Herpesvirus Respiratory Infections in Immunocompromised Patients: Epidemiology, Management, and Outcomes

Abstract

Among immunocompromised individuals, members of the human Herpesviridae family are frequently encountered pathogens. Cytomegalovirus, herpes simplex virus 1 and 2, varicella zoster virus, Epstein–Barr virus, and human herpesvirus-6, -7, and -8 all establish latency after infection and can reactivate during periods of immunosuppression, leading to both direct and indirect adverse effects on the host including severe organ dysfunction as well as allograft rejection and loss after transplantation. While not all herpesviruses are primary respiratory pathogens, many of their manifestations include involvement of the respiratory tract. This article discusses the individual viruses, their epidemiology, and clinical manifestations as well as recommended treatment and preventive strategies.

Keywords

herpesviruses - transplantation - immunodeficiency - viral infection

• References

• 1 Ho M. Epidemiology of cytomegalovirus infections. Rev Infect Dis 1990; 12 (Suppl. 07) S701-S710
• 2 Krech U. Complement-fixing antibodies against cytomegalovirus in different parts of the world. Bull World Health Organ 1973; 49 (1) 103-106
• 3 Rubin RH. Impact of cytomegalovirus infection on organ transplant recipients. Rev Infect Dis 1990; 12 (Suppl. 07) S754-S766
• 4 Kalil AC, Levitsky J, Lyden E, Stoner J, Freifeld AG. Meta-analysis: the efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients. Ann Intern Med 2005; 143 (12) 870-880
• 5 Söderberg-Nauclér C, Fish KN, Nelson JA. Reactivation of latent human cytomegalovirus by allogeneic stimulation of blood cells from healthy donors. Cell 1997; 91 (1) 119-126
• 6 Horwitz CA, Henle W, Henle G , et al. Clinical and laboratory evaluation of cytomegalovirus-induced mononucleosis in previously healthy individuals. Report of 82 cases. Medicine (Baltimore) 1986; 65 (2) 124-134
• 7 Snydman DR, Limaye AP, Potena L, Zamora MR. Update and review: state-of-the-art management of cytomegalovirus infection and disease following thoracic organ transplantation. Transplant Proc 2011; 43 (3, Suppl) S1-S17
• 8 Marcelin JR, Beam E, Razonable RR. Cytomegalovirus infection in liver transplant recipients: updates on clinical management. World J Gastroenterol 2014; 20 (31) 10658-10667
• 9 Chou SW. Acquisition of donor strains of cytomegalovirus by renal-transplant recipients. N Engl J Med 1986; 314 (22) 1418-1423
• 10 Lowance D, Neumayer HH, Legendre CM , et al; International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. N Engl J Med 1999; 340 (19) 1462-1470
• 11 Ljungman P, Griffiths P, Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 2002; 34 (8) 1094-1097
• 12 Gane E, Saliba F, Valdecasas GJ , et al; The Oral Ganciclovir International Transplantation Study Group. Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. The Oral Ganciclovir International Transplantation Study Group [corrected]. [corrected] Lancet 1997; 350 (9093) 1729-1733
• 13 Eid AJ, Arthurs SK, Deziel PJ, Wilhelm MP, Razonable RR. Emergence of drug-resistant cytomegalovirus in the era of valganciclovir prophylaxis: therapeutic implications and outcomes. Clin Transplant 2008; 22 (2) 162-170
• 14 Humar A, Lebranchu Y, Vincenti F , et al. The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients. Am J Transplant 2010; 10 (5) 1228-1237
• 15 Humar A, Snydman D ; AST Infectious Diseases Community of Practice. Cytomegalovirus in solid organ transplant recipients. Am J Transplant 2009; 9 (Suppl. 04) S78-S86
• 16 Paya C, Humar A, Dominguez E , et al; Valganciclovir Solid Organ Transplant Study Group. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2004; 4 (4) 611-620
• 17 Arthurs SK, Eid AJ, Pedersen RA , et al. Delayed-onset primary cytomegalovirus disease and the risk of allograft failure and mortality after kidney transplantation. Clin Infect Dis 2008; 46 (6) 840-846
• 18 Palmer SM, Limaye AP, Banks M , et al. Extended valganciclovir prophylaxis to prevent cytomegalovirus after lung transplantation: a randomized, controlled trial. Ann Intern Med 2010; 152 (12) 761-769
• 19 Singh N. Late-onset cytomegalovirus disease as a significant complication in solid organ transplant recipients receiving antiviral prophylaxis: a call to heed the mounting evidence. Clin Infect Dis 2005; 40 (5) 704-708
• 20 Blyth D, Lee I, Sims KD , et al. Risk factors and clinical outcomes of cytomegalovirus disease occurring more than one year post solid organ transplantation. Transpl Infect Dis 2012; 14 (2) 149-155
• 21 Limaye AP, Bakthavatsalam R, Kim HW , et al. Impact of cytomegalovirus in organ transplant recipients in the era of antiviral prophylaxis. Transplantation 2006; 81 (12) 1645-1652
• 22 Linares L, Sanclemente G, Cervera C , et al. Influence of cytomegalovirus disease in outcome of solid organ transplant patients. Transplant Proc 2011; 43 (6) 2145-2148
• 23 Peleg AY, Husain S, Kwak EJ , et al. Opportunistic infections in 547 organ transplant recipients receiving alemtuzumab, a humanized monoclonal CD-52 antibody. Clin Infect Dis 2007; 44 (2) 204-212
• 24 Ison MG, Fishman JA. Cytomegalovirus pneumonia in transplant recipients. Clin Chest Med 2005; 26 (4) 691-705 , viii
• 25 Fishman JA. Infection in solid-organ transplant recipients. N Engl J Med 2007; 357 (25) 2601-2614
• 26 Lautenschlager I, Halme L, Höckerstedt K, Krogerus L, Taskinen E. Cytomegalovirus infection of the liver transplant: virological, histological, immunological, and clinical observations. Transpl Infect Dis 2006; 8 (1) 21-30
• 27 Razonable RR, Humar A ; AST Infectious Diseases Community of Practice. Cytomegalovirus in solid organ transplantation. Am J Transplant 2013; 13 (Suppl. 04) 93-106
• 28 Hodson EM, Craig JC, Strippoli GF, Webster AC. Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients. Cochrane Database Syst Rev 2008; (2) CD003774
• 29 Sagedal S, Hartmann A, Nordal KP , et al. Impact of early cytomegalovirus infection and disease on long-term recipient and kidney graft survival. Kidney Int 2004; 66 (1) 329-337
• 30 Sagedal S, Rollag H, Hartmann A. Cytomegalovirus infection in renal transplant recipients is associated with impaired survival irrespective of expected mortality risk. Clin Transplant 2007; 21 (3) 309-313
• 31 Koskinen PK, Kallio EA, Tikkanen JM, Sihvola RK, Häyry PJ, Lemström KB. Cytomegalovirus infection and cardiac allograft vasculopathy. Transpl Infect Dis 1999; 1 (2) 115-126
• 32 Erdbruegger U, Scheffner I, Mengel M , et al. Impact of CMV infection on acute rejection and long-term renal allograft function: a systematic analysis in patients with protocol biopsies and indicated biopsies. Nephrol Dial Transplant 2012; 27 (1) 435-443
• 33 Estenne M, Maurer JR, Boehler A , et al. Bronchiolitis obliterans syndrome 2001: an update of the diagnostic criteria. J Heart Lung Transplant 2002; 21 (3) 297-310
• 34 Evans PC, Soin A, Wreghitt TG, Taylor CJ, Wight DG, Alexander GJ. An association between cytomegalovirus infection and chronic rejection after liver transplantation. Transplantation 2000; 69 (1) 30-35
• 35 Humar A, Gillingham KJ, Payne WD, Dunn DL, Sutherland DE, Matas AJ. Association between cytomegalovirus disease and chronic rejection in kidney transplant recipients. Transplantation 1999; 68 (12) 1879-1883
• 36 Kliem V, Fricke L, Wollbrink T, Burg M, Radermacher J, Rohde F. Improvement in long-term renal graft survival due to CMV prophylaxis with oral ganciclovir: results of a randomized clinical trial. Am J Transplant 2008; 8 (5) 975-983
• 37 Kranz B, Vester U, Wingen AM , et al. Acute rejection episodes in pediatric renal transplant recipients with cytomegalovirus infection. Pediatr Transplant 2008; 12 (4) 474-478
• 38 Nett PC, Heisey DM, Fernandez LA, Sollinger HW, Pirsch JD. Association of cytomegalovirus disease and acute rejection with graft loss in kidney transplantation. Transplantation 2004; 78 (7) 1036-1041
• 39 Reischig T, Jindra P, Svecová M, Kormunda S, Opatrný Jr K, Treska V. The impact of cytomegalovirus disease and asymptomatic infection on acute renal allograft rejection. J Clin Virol 2006; 36 (2) 146-151
• 40 Sagedal S, Nordal KP, Hartmann A , et al. The impact of cytomegalovirus infection and disease on rejection episodes in renal allograft recipients. Am J Transplant 2002; 2 (9) 850-856
• 41 Stern M, Hirsch H, Cusini A , et al; Members of Swiss Transplant Cohort Study. Cytomegalovirus serology and replication remain associated with solid organ graft rejection and graft loss in the era of prophylactic treatment. Transplantation 2014; 98 (9) 1013-1018
• 42 Westall GP, Michaelides A, Williams TJ, Snell GI, Kotsimbos TC. Bronchiolitis obliterans syndrome and early human cytomegalovirus DNAaemia dynamics after lung transplantation. Transplantation 2003; 75 (12) 2064-2068
• 43 Paraskeva M, Bailey M, Levvey BJ , et al. Cytomegalovirus replication within the lung allograft is associated with bronchiolitis obliterans syndrome. Am J Transplant 2011; 11 (10) 2190-2196
• 44 Schlischewsky E, Fuehner T, Warnecke G , et al. Clinical significance of quantitative cytomegalovirus detection in bronchoalveolar lavage fluid in lung transplant recipients. Transpl Infect Dis 2013; 15 (1) 60-69
• 45 Valantine HA, Gao SZ, Menon SG , et al. Impact of prophylactic immediate posttransplant ganciclovir on development of transplant atherosclerosis: a post hoc analysis of a randomized, placebo-controlled study. Circulation 1999; 100 (1) 61-66
• 46 Lemström K, Koskinen P, Krogerus L, Daemen M, Bruggeman C, Häyry P. Cytomegalovirus antigen expression, endothelial cell proliferation, and intimal thickening in rat cardiac allografts after cytomegalovirus infection. Circulation 1995; 92 (9) 2594-2604
• 47 Razonable RR, Rivero A, Rodriguez A , et al. Allograft rejection predicts the occurrence of late-onset cytomegalovirus (CMV) disease among CMV-mismatched solid organ transplant patients receiving prophylaxis with oral ganciclovir. J Infect Dis 2001; 184 (11) 1461-1464
• 48 George MJ, Snydman DR, Werner BG , et al. The independent role of cytomegalovirus as a risk factor for invasive fungal disease in orthotopic liver transplant recipients. Boston Center for Liver Transplantation CMVIG-Study Group. Cytogam, MedImmune, Inc. Gaithersburg, Maryland. Am J Med 1997; 103 (2) 106-113
• 49 Hodson EM, Jones CA, Webster AC , et al. Antiviral medications to prevent cytomegalovirus disease and early death in recipients of solid-organ transplants: a systematic review of randomised controlled trials. Lancet 2005; 365 (9477) 2105-2115
• 50 Nichols WG, Corey L, Gooley T, Davis C, Boeckh M. High risk of death due to bacterial and fungal infection among cytomegalovirus (CMV)-seronegative recipients of stem cell transplants from seropositive donors: evidence for indirect effects of primary CMV infection. J Infect Dis 2002; 185 (3) 273-282
• 51 Walker RC, Marshall WF, Strickler JG , et al. Pretransplantation assessment of the risk of lymphoproliferative disorder. Clin Infect Dis 1995; 20 (5) 1346-1353
• 52 Bosch W, Heckman MG, Pungpapong S, Diehl NN, Shalev JA, Hellinger WC. Association of cytomegalovirus infection and disease with recurrent hepatitis C after liver transplantation. Transplantation 2012; 93 (7) 723-728
• 53 Einollahi B, Motalebi M, Salesi M, Ebrahimi M, Taghipour M. The impact of cytomegalovirus infection on new-onset diabetes mellitus after kidney transplantation: a review on current findings. J Nephropathol 2014; 3 (4) 139-148
• 54 Pastacaldi S, Teixeira R, Montalto P, Rolles K, Burroughs AK. Hepatic artery thrombosis after orthotopic liver transplantation: a review of nonsurgical causes. Liver Transpl 2001; 7 (2) 75-81
• 55 Razonable RR, Åsberg A, Rollag H , et al. Virologic suppression measured by a cytomegalovirus (CMV) DNA test calibrated to the World Health Organization international standard is predictive of CMV disease resolution in transplant recipients. Clin Infect Dis 2013; 56 (11) 1546-1553
• 56 Kotton CN. CMV: Prevention, Diagnosis and Therapy. Am J Transplant 2013; 13 (Suppl. 03) 24-40 , quiz 40
• 57 Cope AV, Sabin C, Burroughs A, Rolles K, Griffiths PD, Emery VC. Interrelationships among quantity of human cytomegalovirus (HCMV) DNA in blood, donor-recipient serostatus, and administration of methylprednisolone as risk factors for HCMV disease following liver transplantation. J Infect Dis 1997; 176 (6) 1484-1490
• 58 Emery VC, Sabin CA, Cope AV, Gor D, Hassan-Walker AF, Griffiths PD. Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation. Lancet 2000; 355 (9220) 2032-2036
• 59 Hirsch HH, Lautenschlager I, Pinsky BA , et al. An international multicenter performance analysis of cytomegalovirus load tests. Clin Infect Dis 2013; 56 (3) 367-373
• 60 Caliendo AM, Schuurman R, Yen-Lieberman B , et al; CMV Working Group of the Complications of HIV Disease RAC, AIDS Clinical Trials Group. Comparison of quantitative and qualitative PCR assays for cytomegalovirus DNA in plasma. J Clin Microbiol 2001; 39 (4) 1334-1338
• 61 Grim SA, Pereira E, Guzman G, Clark NM. CMV PCR as a diagnostic tool for CMV gastrointestinal disease after solid organ transplantation. Transplantation 2010; 90 (7) 799-801
• 62 Mazzulli T, Drew LW, Yen-Lieberman B , et al. Multicenter comparison of the digene hybrid capture CMV DNA assay (version 2.0), the pp65 antigenemia assay, and cell culture for detection of cytomegalovirus viremia. J Clin Microbiol 1999; 37 (4) 958-963
• 63 Buffone GJ, Frost A, Samo T, Demmler GJ, Cagle PT, Lawrence EC. The diagnosis of CMV pneumonitis in lung and heart/lung transplant patients by PCR compared with traditional laboratory criteria. Transplantation 1993; 56 (2) 342-347
• 64 Chemaly RF, Yen-Lieberman B, Chapman J , et al. Clinical utility of cytomegalovirus viral load in bronchoalveolar lavage in lung transplant recipients. Am J Transplant 2005; 5 (3) 544-548
• 65 Storch GA, Ettinger NA, Ockner D , et al. Quantitative cultures of the cell fraction and supernatant of bronchoalveolar lavage fluid for the diagnosis of cytomegalovirus pneumonitis in lung transplant recipients. J Infect Dis 1993; 168 (6) 1502-1506
• 66 Westall GP, Michaelides A, Williams TJ, Snell GI, Kotsimbos TC. Human cytomegalovirus load in plasma and bronchoalveolar lavage fluid: a longitudinal study of lung transplant recipients. J Infect Dis 2004; 190 (6) 1076-1083
• 67 Rayes N, Seehofer D, Lullius SG , et al. Monitoring of human cytomegalovirus, HHV-6 and HHV-7 infection in kidney transplant recipients by molecular methods to predict HCMV disease after transplantation: a prospective study. Ann Transplant 2005; 10 (2) 23-28
• 68 Hardie DR, Korsman SN, Hsiao NY. Cytomegalovirus load in whole blood is more reliable for predicting and assessing CMV disease than pp65 antigenaemia. J Virol Methods 2013; 193 (1) 166-168
• 69 Marchetti S, Santangelo R, Manzara S, D'onghia S, Fadda G, Cattani P. Comparison of real-time PCR and pp65 antigen assays for monitoring the development of Cytomegalovirus disease in recipients of solid organ and bone marrow transplants. New Microbiol 2011; 34 (2) 157-164
• 70 Levitsky J, Singh N, Wagener MM, Stosor V, Abecassis M, Ison MG. A survey of CMV prevention strategies after liver transplantation. Am J Transplant 2008; 8 (1) 158-161
• 71 Humar A, Mazzulli T, Moussa G , et al; Valganciclovir Solid Organ Transplant Study Group. Clinical utility of cytomegalovirus (CMV) serology testing in high-risk CMV D+/R- transplant recipients. Am J Transplant 2005; 5 (5) 1065-1070
• 72 Weber B, Fall EM, Berger A, Doerr HW. Screening of blood donors for human cytomegalovirus (HCMV) IgG antibody with an enzyme immunoassay using recombinant antigens. J Clin Virol 1999; 14 (3) 173-181
• 73 Manuel O, Husain S, Kumar D , et al. Assessment of cytomegalovirus-specific cell-mediated immunity for the prediction of cytomegalovirus disease in high-risk solid-organ transplant recipients: a multicenter cohort study. Clin Infect Dis 2013; 56 (6) 817-824
• 74 Montejo M, Montejo E, Gastaca M , et al. Prophylactic therapy with valgancyclovir in high-risk (cytomegalovirus D+/R-) liver transplant recipients: a single-center experience. Transplant Proc 2009; 41 (6) 2189-2191
• 75 Kuo HT, Ye X, Sampaio MS, Reddy P, Bunnapradist S. Cytomegalovirus serostatus pairing and deceased donor kidney transplant outcomes in adult recipients with antiviral prophylaxis. Transplantation 2010; 90 (10) 1091-1098
• 76 Ugarte-Torres A, Hoegh-Petersen M, Liu Y , et al. Donor serostatus has an impact on cytomegalovirus-specific immunity, cytomegaloviral disease incidence, and survival in seropositive hematopoietic cell transplant recipients. Biol Blood Marrow Transplant 2011; 17 (4) 574-585
• 77 Zhou W, Longmate J, Lacey SF , et al. Impact of donor CMV status on viral infection and reconstitution of multifunction CMV-specific T cells in CMV-positive transplant recipients. Blood 2009; 113 (25) 6465-6476
• 78 Ljungman P, Brand R, Hoek J , et al; Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Donor cytomegalovirus status influences the outcome of allogeneic stem cell transplant: a study by the European group for blood and marrow transplantation. Clin Infect Dis 2014; 59 (4) 473-481
• 79 Ariza-Heredia EJ, Nesher L, Chemaly RF. Cytomegalovirus diseases after hematopoietic stem cell transplantation: a mini-review. Cancer Lett 2014; 342 (1) 1-8
• 80 Kotton CN, Kumar D, Caliendo AM , et al; Transplantation Society International CMV Consensus Group. Updated international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. Transplantation 2013; 96 (4) 333-360
• 81 Portela D, Patel R, Larson-Keller JJ , et al. OKT3 treatment for allograft rejection is a risk factor for cytomegalovirus disease in liver transplantation. J Infect Dis 1995; 171 (4) 1014-1018
• 82 Brown RA, Gralewski JH, Razonable RR. The R753Q polymorphism abrogates toll-like receptor 2 signaling in response to human cytomegalovirus. Clin Infect Dis 2009; 49 (9) e96-e99
• 83 Cervera C, Lozano F, Linares L , et al. Influence of mannose-binding lectin gene polymorphisms on the invasiveness of cytomegalovirus disease after solid organ transplantation. Transplant Proc 2009; 41 (6) 2259-2261
• 84 Kang SH, Abdel-Massih RC, Brown RA, Dierkhising RA, Kremers WK, Razonable RR. Homozygosity for the toll-like receptor 2 R753Q single-nucleotide polymorphism is a risk factor for cytomegalovirus disease after liver transplantation. J Infect Dis 2012; 205 (4) 639-646
• 85 Cervera C, Lozano F, Saval N , et al. The influence of innate immunity gene receptors polymorphisms in renal transplant infections. Transplantation 2007; 83 (11) 1493-1500
• 86 Kwakkel-van Erp JM, Paantjens AW, van Kessel DA , et al. Mannose-binding lectin deficiency linked to cytomegalovirus (CMV) reactivation and survival in lung transplantation. Clin Exp Immunol 2011; 165 (3) 410-416
• 87 Abate D, Saldan A, Mengoli C , et al. Comparison of cytomegalovirus (CMV) enzyme-linked immunosorbent spot and CMV quantiferon gamma interferon-releasing assays in assessing risk of CMV infection in kidney transplant recipients. J Clin Microbiol 2013; 51 (8) 2501-2507
• 88 Goldfarb NS, Avery RK, Goormastic M , et al. Hypogammaglobulinemia in lung transplant recipients. Transplantation 2001; 71 (2) 242-246
• 89 Cytovene [package insert]. San Francisco, CA: Genetech, Inc; 2010
• 90 Asberg A, Humar A, Rollag H , et al; VICTOR Study Group. Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2007; 7 (9) 2106-2113
• 91 Asberg A, Humar A, Jardine AG , et al; VICTOR Study Group. Long-term outcomes of CMV disease treatment with valganciclovir versus IV ganciclovir in solid organ transplant recipients. Am J Transplant 2009; 9 (5) 1205-1213
• 92 Humar A, Kumar D, Boivin G, Caliendo AM. Cytomegalovirus (CMV) virus load kinetics to predict recurrent disease in solid-organ transplant patients with CMV disease. J Infect Dis 2002; 186 (6) 829-833
• 93 Sullivan T, Brodginski A, Patel G, Huprikar S. The role of secondary cytomegalovirus prophylaxis for kidney and liver transplant recipients. Transplantation 2015; 99 (4) 855-859
• 94 Alexander BT, Hladnik LM, Augustin KM , et al. Use of cytomegalovirus intravenous immune globulin for the adjunctive treatment of cytomegalovirus in hematopoietic stem cell transplant recipients. Pharmacotherapy 2010; 30 (6) 554-561
• 95 Boivin G, Goyette N, Gilbert C, Humar A, Covington E. Clinical impact of ganciclovir-resistant cytomegalovirus infections in solid organ transplant patients. Transpl Infect Dis 2005; 7 (3–4) 166-170
• 96 Limaye AP, Corey L, Koelle DM, Davis CL, Boeckh M. Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants. Lancet 2000; 356 (9230) 645-649
• 97 Lurain NS, Chou S. Antiviral drug resistance of human cytomegalovirus. Clin Microbiol Rev 2010; 23 (4) 689-712
• 98 Minces LR, Nguyen MH, Mitsani D , et al. Ganciclovir-resistant cytomegalovirus infections among lung transplant recipients are associated with poor outcomes despite treatment with foscarnet-containing regimens. Antimicrob Agents Chemother 2014; 58 (1) 128-135
• 99 Mylonakis E, Kallas WM, Fishman JA. Combination antiviral therapy for ganciclovir-resistant cytomegalovirus infection in solid-organ transplant recipients. Clin Infect Dis 2002; 34 (10) 1337-1341
• 100 Zuk DM, Humar A, Weinkauf JG, Lien DC, Nador RG, Kumar D. An international survey of cytomegalovirus management practices in lung transplantation. Transplantation 2010; 90 (6) 672-676
• 101 Nashan B, Gaston R, Emery V , et al. Review of cytomegalovirus infection findings with mammalian target of rapamycin inhibitor-based immunosuppressive therapy in de novo renal transplant recipients. Transplantation 2012; 93 (11) 1075-1085
• 102 Alain S, Revest M, Veyer D , et al. Maribavir use in practice for cytomegalovirus infection in French transplantation centers. Transplant Proc 2013; 45 (4) 1603-1607
• 103 Avery RK, Marty FM, Strasfeld L , et al. Oral maribavir for treatment of refractory or resistant cytomegalovirus infections in transplant recipients. Transpl Infect Dis 2010; 12 (6) 489-496
• 104 Chou S, Komazin-Meredith G, Williams JD, Bowlin TL. Cytomegalovirus mutants resistant to ganciclovir and cidofovir differ in susceptibilities to synguanol and its 6-ether and 6-thioether derivatives. Antimicrob Agents Chemother 2014; 58 (3) 1809-1812
• 105 Härter G, Michel D. Antiviral treatment of cytomegalovirus infection: an update. Expert Opin Pharmacother 2012; 13 (5) 623-627
• 106 Kaul DR, Stoelben S, Cober E , et al. First report of successful treatment of multidrug-resistant cytomegalovirus disease with the novel anti-CMV compound AIC246. Am J Transplant 2011; 11 (5) 1079-1084
• 107 Levi ME, Mandava N, Chan LK, Weinberg A, Olson JL. Treatment of multidrug-resistant cytomegalovirus retinitis with systemically administered leflunomide. Transpl Infect Dis 2006; 8 (1) 38-43
• 108 Marschall M, Stamminger T, Urban A , et al. In vitro evaluation of the activities of the novel anticytomegalovirus compound AIC246 (letermovir) against herpesviruses and other human pathogenic viruses. Antimicrob Agents Chemother 2012; 56 (2) 1135-1137
• 109 Florescu D, Mercer D, Grimley M , et al. Brincidofovir (CMX001) for the treatment of serious or life-threatening double-stranded DNA virus infections in patients receiving liver transplant as part of multiorgan transplantation. Paper presented at: World Transplant Congress; July 26–31, 2014; San Francisco, CA. Abstract A2979
• 110 Mullane K, Florescu D, Kwak EJ , et al. Brincidofovir (CMX001) experience in renal transplant patients for treatment of refractory CMV infection. Paper presented at: World Transplant Congress; July 26–31, 2014; San Francisco, CA. Abstract D2364
• 111 Painter W, Robertson A, Trost LC, Godkin S, Lampert B, Painter G. First pharmacokinetic and safety study in humans of the novel lipid antiviral conjugate CMX001, a broad-spectrum oral drug active against double-stranded DNA viruses. Antimicrob Agents Chemother 2012; 56 (5) 2726-2734
• 112 Aspord C, Laurin D, Richard MJ, Vie H, Chaperot L, Plumas J. Induction of antiviral cytotoxic T cells by plasmacytoid dendritic cells for adoptive immunotherapy of posttransplant diseases. Am J Transplant 2011; 11 (12) 2613-2626
• 113 Gerdemann U, Katari UL, Papadopoulou A , et al. Safety and clinical efficacy of rapidly-generated trivirus-directed T cells as treatment for adenovirus, EBV, and CMV infections after allogeneic hematopoietic stem cell transplant. Mol Ther 2013; 21 (11) 2113-2121
• 114 Bodro M, Sabé N, Lladó L , et al. Prophylaxis versus preemptive therapy for cytomegalovirus disease in high-risk liver transplant recipients. Liver Transpl 2012; 18 (9) 1093-1099
• 115 Lautenschlager I, Loginov R, Mäkisalo H, Höckerstedt K. Prospective study on CMV-reactivations under preemptive strategy in CMV-seropositive adult liver transplant recipients. J Clin Virol 2013; 57 (1) 50-53
• 116 Small LN, Lau J, Snydman DR. Preventing post-organ transplantation cytomegalovirus disease with ganciclovir: a meta-analysis comparing prophylactic and preemptive therapies. Clin Infect Dis 2006; 43 (7) 869-880
• 117 Opelz G, Döhler B, Ruhenstroth A. Cytomegalovirus prophylaxis and graft outcome in solid organ transplantation: a collaborative transplant study report. Am J Transplant 2004; 4 (6) 928-936
• 118 Opelz G, Döhler B. Reduced rate of cardiovascular death after cytomegalovirus prophylaxis in renal transplant recipients. Transplantation 2015; 99 (6) 1197-1202
• 119 Malouf MA, Chhajed PN, Hopkins P, Plit M, Turner J, Glanville AR. Anti-viral prophylaxis reduces the incidence of lymphoproliferative disease in lung transplant recipients. J Heart Lung Transplant 2002; 21 (5) 547-554
• 120 Munoz-Price LS, Slifkin M, Ruthazer R , et al. The clinical impact of ganciclovir prophylaxis on the occurrence of bacteremia in orthotopic liver transplant recipients. Clin Infect Dis 2004; 39 (9) 1293-1299
• 121 Florescu DF, Qiu F, Schmidt CM, Kalil AC. A direct and indirect comparison meta-analysis on the efficacy of cytomegalovirus preventive strategies in solid organ transplant. Clin Infect Dis 2014; 58 (6) 785-803
• 122 Manuel O, Kralidis G, Mueller NJ , et al; Swiss Transplant Cohort Study. Impact of antiviral preventive strategies on the incidence and outcomes of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2013; 13 (9) 2402-2410
• 123 Khoury JA, Storch GA, Bohl DL , et al. Prophylactic versus preemptive oral valganciclovir for the management of cytomegalovirus infection in adult renal transplant recipients. Am J Transplant 2006; 6 (9) 2134-2143
• 124 Reischig T, Jindra P, Hes O, Svecová M, Klaboch J, Treska V. Valacyclovir prophylaxis versus preemptive valganciclovir therapy to prevent cytomegalovirus disease after renal transplantation. Am J Transplant 2008; 8 (1) 69-77
• 125 Witzke O, Hauser IA, Bartels M, Wolf G, Wolters H, Nitschke M ; VIPP Study Group. Valganciclovir prophylaxis versus preemptive therapy in cytomegalovirus-positive renal allograft recipients: 1-year results of a randomized clinical trial. Transplantation 2012; 93 (1) 61-68
• 126 Couzi L, Helou S, Bachelet T , et al. High incidence of anticytomegalovirus drug resistance among D+R- kidney transplant recipients receiving preemptive therapy. Am J Transplant 2012; 12 (1) 202-209
• 127 Kruger RM, Shannon WD, Arens MQ, Lynch JP, Storch GA, Trulock EP. The impact of ganciclovir-resistant cytomegalovirus infection after lung transplantation. Transplantation 1999; 68 (9) 1272-1279
• 128 Limaye AP, Raghu G, Koelle DM, Ferrenberg J, Huang ML, Boeckh M. High incidence of ganciclovir-resistant cytomegalovirus infection among lung transplant recipients receiving preemptive therapy. J Infect Dis 2002; 185 (1) 20-27
• 129 Boeckh M, Nichols WG, Chemaly RF , et al. Valganciclovir for the prevention of complications of late cytomegalovirus infection after allogeneic hematopoietic cell transplantation: a randomized trial. Ann Intern Med 2015; 162 (1) 1-10
• 130 Snydman DR, Falagas ME, Avery R , et al. Use of combination cytomegalovirus immune globulin plus ganciclovir for prophylaxis in CMV-seronegative liver transplant recipients of a CMV-seropositive donor organ: a multicenter, open-label study. Transplant Proc 2001; 33 (4) 2571-2575
• 131 Snydman DR, Werner BG, Dougherty NN , et al; Boston Center for Liver Transplantation CMVIG Study Group. Cytomegalovirus immune globulin prophylaxis in liver transplantation. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1993; 119 (10) 984-991
• 132 Zamora MR, Nicolls MR, Hodges TN , et al. Following universal prophylaxis with intravenous ganciclovir and cytomegalovirus immune globulin, valganciclovir is safe and effective for prevention of CMV infection following lung transplantation. Am J Transplant 2004; 4 (10) 1635-1642
• 133 Stevens DR, Sawinski D, Blumberg E, Galanakis N, Bloom RD, Trofe-Clark J. Increased risk of breakthrough infection among cytomegalovirus donor-positive/recipient-negative kidney transplant recipients receiving lower-dose valganciclovir prophylaxis. Transpl Infect Dis 2015; 17 (2) 163-173
• 134 Winston DJ, Saliba F, Blumberg E , et al; 1263-301 Clinical Study Group. Efficacy and safety of maribavir dosed at 100 mg orally twice daily for the prevention of cytomegalovirus disease in liver transplant recipients: a randomized, double-blind, multicenter controlled trial. Am J Transplant 2012; 12 (11) 3021-3030
• 135 Marty FM, Ljungman P, Papanicolaou GA , et al; Maribavir 1263-300 Clinical Study Group. Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial. Lancet Infect Dis 2011; 11 (4) 284-292
• 136 Chemaly RF, Ullmann AJ, Stoelben S , et al; AIC246 Study Team. Letermovir for cytomegalovirus prophylaxis in hematopoietic-cell transplantation. N Engl J Med 2014; 370 (19) 1781-1789
• 137 Marty FM, Winston DJ, Rowley SD , et al; CMX001-201 Clinical Study Group. CMX001 to prevent cytomegalovirus disease in hematopoietic-cell transplantation. N Engl J Med 2013; 369 (13) 1227-1236
• 138 Wiita AP, Roubinian N, Khan Y , et al. Cytomegalovirus disease and infection in lung transplant recipients in the setting of planned indefinite valganciclovir prophylaxis. Transpl Infect Dis 2012; 14 (3) 248-258
• 139 Gerna G, Lilleri D, Callegaro A , et al. Prophylaxis followed by preemptive therapy versus preemptive therapy for prevention of human cytomegalovirus disease in pediatric patients undergoing liver transplantation. Transplantation 2008; 86 (1) 163-166
• 140 Humar A, Paya C, Pescovitz MD , et al. Clinical utility of cytomegalovirus viral load testing for predicting CMV disease in D+/R- solid organ transplant recipients. Am J Transplant 2004; 4 (4) 644-649
• 141 Lisboa LF, Preiksaitis JK, Humar A, Kumar D. Clinical utility of molecular surveillance for cytomegalovirus after antiviral prophylaxis in high-risk solid organ transplant recipients. Transplantation 2011; 92 (9) 1063-1068
• 142 Kumar D, Chernenko S, Moussa G , et al. Cell-mediated immunity to predict cytomegalovirus disease in high-risk solid organ transplant recipients. Am J Transplant 2009; 9 (5) 1214-1222
• 143 Westall GP, Mifsud NA, Kotsimbos T. Linking CMV serostatus to episodes of CMV reactivation following lung transplantation by measuring CMV-specific CD8+ T-cell immunity. Am J Transplant 2008; 8 (8) 1749-1754
• 144 Weseslindtner L, Kerschner H, Steinacher D , et al. Prospective analysis of human cytomegalovirus DNAemia and specific CD8+ T cell responses in lung transplant recipients. Am J Transplant 2012; 12 (8) 2172-2180
• 145 Griffiths PD, Stanton A, McCarrell E , et al. Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial. Lancet 2011; 377 (9773) 1256-1263
• 146 Kharfan-Dabaja MA, Boeckh M, Wilck MB , et al. A novel therapeutic cytomegalovirus DNA vaccine in allogeneic haemopoietic stem-cell transplantation: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Infect Dis 2012; 12 (4) 290-299
• 147 Rieder F, Steininger C. Cytomegalovirus vaccine: phase II clinical trial results. Clin Microbiol Infect 2014; 20 (Suppl. 05) 95-102
• 148 Salimnia H, Fairfax MR, Chandrasekar PH. Detection and pharmacokinetics of a cytomegalovirus (CMV) DNA plasmid in human plasma during a clinical trial of an intramuscular CMV vaccine in hematopoietic stem cell transplant recipients. Transpl Infect Dis 2014; 16 (6) 914-918
• 149 A study to evaluate a therapeutic vaccine, ASP0113, in cytomegalovirus (CMV)-seropositive recipients undergoing allogeneic, hematopoietic cell transplant (HCT) (HELIOS). Available at: http://www.clinicaltrials.gov/ct2/show/NCT01877655?term=transvax+and+phase+3&rank=1 . Accessed June 22, 2016
• 150 Crawford DH. Biology and disease associations of Epstein-Barr virus. Philos Trans R Soc Lond B Biol Sci 2001; 356 (1408) 461-473
• 151 Pereira MS, Blake JM, Macrae AD. EB virus antibody at different ages. BMJ 1969; 4 (5682) 526-527
• 152 Tischendorf P, Shramek GJ, Balagtas RC , et al. Development and persistence of immunity to Epstein-Barr virus in man. J Infect Dis 1970; 122 (5) 401-409
• 153 Balfour Jr HH, Sifakis F, Sliman JA, Knight JA, Schmeling DO, Thomas W. Age-specific prevalence of Epstein-Barr virus infection among individuals aged 6-19 years in the United States and factors affecting its acquisition. J Infect Dis 2013; 208 (8) 1286-1293
• 154 Henle G, Henle W. Immunofluorescence, interference, and complement fixation technics in the detection of the herpes-type virus in Burkitt tumor cell lines. Cancer Res 1967; 27 (12) 2442-2446
• 155 Porter DD, Wimberly I, Benyesh-Melnick M. Prevalence of antibodies to EB virus and other herpesviruses. JAMA 1969; 208 (9) 1675-1679
• 156 Higgins CD, Swerdlow AJ, Macsween KF , et al. A study of risk factors for acquisition of Epstein-Barr virus and its subtypes. J Infect Dis 2007; 195 (4) 474-482
• 157 Allen U, Alfieri C, Preiksaitis J , et al; Canadian PTLD Workshop Group - 1999. Epstein-Barr virus infection in transplant recipients: Summary of a workshop on surveillance, prevention and treatment. Can J Infect Dis Med Microbiol 2002; 13 (2) 89-99
• 158 Allen UD, Preiksaitis JK ; AST Infectious Diseases Community of Practice. Epstein-Barr virus and posttransplant lymphoproliferative disorder in solid organ transplantation. Am J Transplant 2013; 13 (Suppl. 04) 107-120
• 159 Thorley-Lawson DA, Hawkins JB, Tracy SI, Shapiro M. The pathogenesis of Epstein-Barr virus persistent infection. Curr Opin Virol 2013; 3 (3) 227-232
• 160 de-Thé G, Geser A, Day NE , et al. Epidemiological evidence for causal relationship between Epstein-Barr virus and Burkitt's lymphoma from Ugandan prospective study. Nature 1978; 274 (5673) 756-761
• 161 Epstein MA, Achong BG, Barr YM. Virus Particles in Cultured Lymphoblasts from Burkitt's Lymphoma. Lancet 1964; 1 (7335) 702-703
• 162 Hjalgrim H, Askling J, Rostgaard K , et al. Characteristics of Hodgkin's lymphoma after infectious mononucleosis. N Engl J Med 2003; 349 (14) 1324-1332
• 163 Cohen JI. Epstein-Barr virus infection. N Engl J Med 2000; 343 (7) 481-492
• 164 Forte E, Luftig MA. The role of microRNAs in Epstein-Barr virus latency and lytic reactivation. Microbes Infect 2011; 13 (14–15) 1156-1167
• 165 Clark NM, Lynch III JP, Sayah D, Belperio JA, Fishbein MC, Weigt SS. DNA viral infections complicating lung transplantation. Semin Respir Crit Care Med 2013; 34 (3) 380-404
• 166 Nourse JP, Jones K, Gandhi MK. Epstein-Barr virus-related post-transplant lymphoproliferative disorders: pathogenetic insights for targeted therapy. Am J Transplant 2011; 11 (5) 888-895
• 167 Gulley ML, Swinnen LJ, Plaisance Jr KT, Schnell C, Grogan TM, Schneider BG ; Southwest Oncology Group. Tumor origin and CD20 expression in posttransplant lymphoproliferative disorder occurring in solid organ transplant recipients: implications for immune-based therapy. Transplantation 2003; 76 (6) 959-964
• 168 Verschuuren E, van der Bij W, de Boer W, Timens W, Middeldorp J, The TH. Quantitative Epstein-Barr virus (EBV) serology in lung transplant recipients with primary EBV infection and/or post-transplant lymphoproliferative disease. J Med Virol 2003; 69 (2) 258-266
• 169 Kinch A, Cavelier L, Bengtsson M , et al. Donor or recipient origin of posttransplant lymphoproliferative disorders following solid organ transplantation. Am J Transplant 2014; 14 (12) 2838-2845
• 170 Olagne J, Caillard S, Gaub MP, Chenard MP, Moulin B. Post-transplant lymphoproliferative disorders: determination of donor/recipient origin in a large cohort of kidney recipients. Am J Transplant 2011; 11 (6) 1260-1269
• 171 Sanz J, Arango M, Senent L , et al. EBV-associated post-transplant lymphoproliferative disorder after umbilical cord blood transplantation in adults with hematological diseases. Bone Marrow Transplant 2014; 49 (3) 397-402
• 172 Dierickx D, Tousseyn T, Gheysens O. How I treat posttransplant lymphoproliferative disorders. Blood 2015; 126 (20) 2274-2283
• 173 Caillard S, Lamy FX, Quelen C , et al; French Transplant Centers. Epidemiology of posttransplant lymphoproliferative disorders in adult kidney and kidney pancreas recipients: report of the French registry and analysis of subgroups of lymphomas. Am J Transplant 2012; 12 (3) 682-693
• 174 Tai R, Tirumani SH, Tirumani H, Shinagare AB, Hornick JL, Ramaiya NH. Is there a difference in post-transplant lymphoproliferative disorder in adults after solid organ and haematologic stem cell transplantation? Experience in 41 patients. Br J Radiol 2015; 88 (1052) 20140861
• 175 Xu LP, Zhang CL, Mo XD , et al. Epstein-Barr virus-related post-transplantation lymphoproliferative disorder after unmanipulated human leukocyte antigen haploidentical hematopoietic stem cell transplantation: incidence, risk factors, treatment, and clinical outcomes. Biol Blood Marrow Transplant 2015; 21 (12) 2185-2191
• 176 Jenson HB. Epstein-Barr virus. Pediatr Rev 2011; 32 (9) 375-383 , quiz 384
• 177 Muchtar E, Kramer MR, Vidal L , et al. Posttransplantation lymphoproliferative disorder in lung transplant recipients: a 15-year single institution experience. Transplantation 2013; 96 (7) 657-663
• 178 Vakiani E, Basso K, Klein U , et al. Genetic and phenotypic analysis of B-cell post-transplant lymphoproliferative disorders provides insights into disease biology. Hematol Oncol 2008; 26 (4) 199-211
• 179 Green M, Michaels MG. Epstein-Barr virus infection and posttransplant lymphoproliferative disorder. Am J Transplant 2013; 13 (Suppl. 03) 41-54 , quiz 54
• 180 Kremer BE, Reshef R, Misleh JG , et al. Post-transplant lymphoproliferative disorder after lung transplantation: a review of 35 cases. J Heart Lung Transplant 2012; 31 (3) 296-304
• 181 Franquet T. Imaging of pulmonary viral pneumonia. Radiology 2011; 260 (1) 18-39
• 182 Krumbholz A, Sandhaus T, Göhlert A , et al. Epstein-Barr virus-associated pneumonia and bronchiolitis obliterans syndrome in a lung transplant recipient. Med Microbiol Immunol (Berl) 2010; 199 (4) 317-322
• 183 Thijsen SF, Luderer R, van Gorp JM, Oudejans SJ, Bossink AW. A possible role for Epstein-Barr virus in the pathogenesis of pleural effusion. Eur Respir J 2005; 26 (4) 662-666
• 184 Takei H, Mody D. Epstein-Barr virus-positive pleural effusion: Clinical features, cytomorphologic characteristics, and flow cytometric immunophenotyping. Am J Clin Pathol 2014; 142 (6) 788-794
• 185 Brescia AA, Khullar OV, Gal AA, Neujahr D, Force SD. Epstein-Barr virus-associated pulmonary smooth muscle tumor after lung transplantation. Ann Thorac Surg 2015; 99 (6) e145-e146
• 186 Huang J, Loh KS, Petersson F. Epstein-barr virus-associated smooth muscle tumor of the larynx: report of a rare case mimicking leiomyosarcoma. Head Neck Pathol 2010; 4 (4) 300-304
• 187 Tsai DE, Douglas L, Andreadis C , et al. EBV PCR in the diagnosis and monitoring of posttransplant lymphoproliferative disorder: results of a two-arm prospective trial. Am J Transplant 2008; 8 (5) 1016-1024
• 188 Michelson P, Watkins B, Webber SA, Wadowsky R, Michaels MG. Screening for PTLD in lung and heart-lung transplant recipients by measuring EBV DNA load in bronchoalveolar lavage fluid using real time PCR. Pediatr Transplant 2008; 12 (4) 464-468
• 189 Liu QF, Fan ZP, Luo XD, Sun J, Zhang Y, Ding YQ. Epstein-Barr virus-associated pneumonia in patients with post-transplant lymphoproliferative disease after hematopoietic stem cell transplantation. Transpl Infect Dis 2010; 12 (4) 284-291
• 190 Panagiotidis E, Quigley AM, Pencharz D , et al. (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in diagnosis of post-transplant lymphoproliferative disorder. Leuk Lymphoma 2014; 55 (3) 515-519
• 191 Bustami RT, Ojo AO, Wolfe RA , et al. Immunosuppression and the risk of post-transplant malignancy among cadaveric first kidney transplant recipients. Am J Transplant 2004; 4 (1) 87-93
• 192 Opelz G, Döhler B. Lymphomas after solid organ transplantation: a collaborative transplant study report. Am J Transplant 2004; 4 (2) 222-230
• 193 Duvoux C, Pageaux GP, Vanlemmens C , et al. Risk factors for lymphoproliferative disorders after liver transplantation in adults: an analysis of 480 patients. Transplantation 2002; 74 (8) 1103-1109
• 194 Sundin M, Le Blanc K, Ringdén O , et al. The role of HLA mismatch, splenectomy and recipient Epstein-Barr virus seronegativity as risk factors in post-transplant lymphoproliferative disorder following allogeneic hematopoietic stem cell transplantation. Haematologica 2006; 91 (8) 1059-1067
• 195 Aull MJ, Buell JF, Trofe J , et al. Experience with 274 cardiac transplant recipients with posttransplant lymphoproliferative disorder: a report from the Israel Penn International Transplant Tumor Registry. Transplantation 2004; 78 (11) 1676-1682
• 196 Reshef R, Vardhanabhuti S, Luskin MR , et al. Reduction of immunosuppression as initial therapy for posttransplantation lymphoproliferative disorder. Am J Transplant 2011; 11 (2) 336-347
• 197 Petrara MR, Giunco S, Serraino D, Dolcetti R, De Rossi A. Post-transplant lymphoproliferative disorders: from epidemiology to pathogenesis-driven treatment. Cancer Lett 2015; 369 (1) 37-44
• 198 Taplitz RA, Jordan MC. Pneumonia caused by herpesviruses in recipients of hematopoietic cell transplants. Semin Respir Infect 2002; 17 (2) 121-129
• 199 Schauer E, Webber S, Kingsley L, Green M, Rowe D. Increased Ig-null B lymphocytes in the peripheral blood of pediatric solid organ transplant recipients with elevated Epstein-Barr viral loads. Pediatr Transplant 2009; 13 (3) 311-318
• 200 Friedrichs C, Neyts J, Gaspar G, De Clercq E, Wutzler P. Evaluation of antiviral activity against human herpesvirus 8 (HHV-8) and Epstein-Barr virus (EBV) by a quantitative real-time PCR assay. Antiviral Res 2004; 62 (3) 121-123
• 201 Keever-Taylor CA, Behn B, Konings S, Orentas R, Davies B, Margolis D. Suppression of EBV release from irradiated B lymphoblastoid cell-lines: superior activity of ganciclovir compared with acyclovir. Cytotherapy 2003; 5 (4) 323-335
• 202 Chan TS, Hwang YY, Gill H , et al. Post-transplant lymphoproliferative diseases in Asian solid organ transplant recipients: late onset and favorable response to treatment. Clin Transplant 2012; 26 (5) 679-683
• 203 Elstrom RL, Andreadis C, Aqui NA , et al. Treatment of PTLD with rituximab or chemotherapy. Am J Transplant 2006; 6 (3) 569-576
• 204 Orjuela MA, Alobeid B, Liu X , et al. CD20 expression predicts survival in paediatric post-transplant lymphoproliferative disease (PTLD) following solid organ transplantation. Br J Haematol 2011; 152 (6) 733-742
• 205 Trappe R, Oertel S, Leblond V , et al; German PTLD Study Group; European PTLD Network. Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial. Lancet Oncol 2012; 13 (2) 196-206
• 206 Bollard CM, Gottschalk S, Torrano V , et al. Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins. J Clin Oncol 2014; 32 (8) 798-808
• 207 Doubrovina E, Oflaz-Sozmen B, Prockop SE , et al. Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation. Blood 2012; 119 (11) 2644-2656
• 208 Sherritt MA, Bharadwaj M, Burrows JM , et al. Reconstitution of the latent T-lymphocyte response to Epstein-Barr virus is coincident with long-term recovery from posttransplant lymphoma after adoptive immunotherapy. Transplantation 2003; 75 (9) 1556-1560
• 209 Styczynski J, Einsele H, Gil L, Ljungman P. Outcome of treatment of Epstein-Barr virus-related post-transplant lymphoproliferative disorder in hematopoietic stem cell recipients: a comprehensive review of reported cases. Transpl Infect Dis 2009; 11 (5) 383-392
• 210 Cullis B, D'Souza R, McCullagh P , et al. Sirolimus-induced remission of posttransplantation lymphoproliferative disorder. Am J Kidney Dis 2006; 47 (5) e67-e72
• 211 Boratyńska M, Smolska D. Inhibition of mTOR by sirolimus induces remission of post-transplant lymphoproliferative disorders. Transpl Int 2008; 21 (6) 605-608
• 212 Boratyńska M, Watorek E, Smolska D, Patrzałek D, Klinger M. Anticancer effect of sirolimus in renal allograft recipients with de novo malignancies. Transplant Proc 2007; 39 (9) 2736-2739
• 213 Ashrafi F, Shahidi S, Ebrahimi Z, Mortazavi M. Outcome of rapamycin therapy for post-transplant-lymphoproliferative disorder after kidney transplantation: case series. Int J Hematol Oncol Stem Cell Res 2015; 9 (1) 26-32
• 214 Krams SM, Martinez OM. Epstein-Barr virus, rapamycin, and host immune responses. Curr Opin Organ Transplant 2008; 13 (6) 563-568
• 215 Opelz G, Daniel V, Naujokat C, Fickenscher H, Döhler B. Effect of cytomegalovirus prophylaxis with immunoglobulin or with antiviral drugs on post-transplant non-Hodgkin lymphoma: a multicentre retrospective analysis. Lancet Oncol 2007; 8 (3) 212-218
• 216 Humar A. Reactivation of viruses in solid organ transplant patients receiving cytomegalovirus prophylaxis. Transplantation 2006; 82 (2, Suppl) S9-S14
• 217 Höcker B, Böhm S, Fickenscher H , et al. (Val-)Ganciclovir prophylaxis reduces Epstein-Barr virus primary infection in pediatric renal transplantation. Transpl Int 2012; 25 (7) 723-731
• 218 Jaksch P, Wiedemann D, Kocher A, Muraközy G, Augustin V, Klepetko W. Effect of cytomegalovirus immunoglobulin on the incidence of lymphoproliferative disease after lung transplantation: single-center experience with 1157 patients. Transplantation 2013; 95 (5) 766-772
• 219 Green M, Michaels MG, Katz BZ , et al. CMV-IVIG for prevention of Epstein Barr virus disease and posttransplant lymphoproliferative disease in pediatric liver transplant recipients. Am J Transplant 2006; 6 (8) 1906-1912
• 220 Humar A, Hébert D, Davies HD , et al. A randomized trial of ganciclovir versus ganciclovir plus immune globulin for prophylaxis against Epstein-Barr virus related posttransplant lymphoproliferative disorder. Transplantation 2006; 81 (6) 856-861
• 221 Manlhiot C, Pollock-Barziv SM, Holmes C , et al. Post-transplant lymphoproliferative disorder in pediatric heart transplant recipients. J Heart Lung Transplant 2010; 29 (6) 648-657
• 222 Funch DP, Walker AM, Schneider G, Ziyadeh NJ, Pescovitz MD. Ganciclovir and acyclovir reduce the risk of post-transplant lymphoproliferative disorder in renal transplant recipients. Am J Transplant 2005; 5 (12) 2894-2900
• 223 Hierro L, Díez-Dorado R, Díaz C , et al. Efficacy and safety of valganciclovir in liver-transplanted children infected with Epstein-Barr virus. Liver Transpl 2008; 14 (8) 1185-1193
• 224 Venturi C, Bueno J, Gavalda J , et al. Impact of valganciclovir on Epstein-Barr virus polymerase chain reaction in pediatric liver transplantation: preliminary report. Transplant Proc 2009; 41 (3) 1038-1040
• 225 Xu F, Sternberg MR, Kottiri BJ , et al. Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States. JAMA 2006; 296 (8) 964-973
• 226 Tronstein E, Johnston C, Huang ML , et al. Genital shedding of herpes simplex virus among symptomatic and asymptomatic persons with HSV-2 infection. JAMA 2011; 305 (14) 1441-1449
• 227 Nahmias AJ, Roizman B. Infection with herpes-simplex viruses 1 and 2. N Engl J Med 1973; 289 (15) 781-789
• 228 Corey L, Spear PG. Infections with herpes simplex viruses. N Engl J Med 1986; 314 (11) 686-691
• 229 Engelberg R, Carrell D, Krantz E, Corey L, Wald A. Natural history of genital herpes simplex virus type 1 infection. Sex Transm Dis 2003; 30 (2) 174-177
• 230 Lafferty WE, Coombs RW, Benedetti J, Critchlow C, Corey L. Recurrences after oral and genital herpes simplex virus infection. Influence of site of infection and viral type. N Engl J Med 1987; 316 (23) 1444-1449
• 231 Whitley RJ. Viral encephalitis. N Engl J Med 1990; 323 (4) 242-250
• 232 Singh N, Dummer JS, Kusne S , et al. Infections with cytomegalovirus and other herpesviruses in 121 liver transplant recipients: transmission by donated organ and the effect of OKT3 antibodies. J Infect Dis 1988; 158 (1) 124-131
• 233 Simoons-Smit AM, Kraan EM, Beishuizen A, Strack van Schijndel RJ, Vandenbroucke-Grauls CM. Herpes simplex virus type 1 and respiratory disease in critically-ill patients: Real pathogen or innocent bystander?. Clin Microbiol Infect 2006; 12 (11) 1050-1059
• 234 Smyth RL, Higenbottam TW, Scott JP , et al. Herpes simplex virus infection in heart-lung transplant recipients. Transplantation 1990; 49 (4) 735-739
• 235 Engelmann I, Gottlieb J, Meier A , et al. Clinical relevance of and risk factors for HSV-related tracheobronchitis or pneumonia: results of an outbreak investigation. Crit Care 2007; 11 (6) R119
• 236 Brodoefel H, Vogel M, Spira D , et al. Herpes-Simplex-Virus 1 pneumonia in the immunocompromised host: high-resolution CT patterns in correlation to outcome and follow-up. Eur J Radiol 2012; 81 (4) e415-e420
• 237 Kusne S, Schwartz M, Breinig MK , et al. Herpes simplex virus hepatitis after solid organ transplantation in adults. J Infect Dis 1991; 163 (5) 1001-1007
• 238 Lepiller Q, Sueur C, Solis M , et al. Clinical relevance of herpes simplex virus viremia in Intensive Care Unit patients. J Infect 2015; 71 (1) 93-100
• 239 Ramaswamy M, McDonald C, Smith M , et al. Diagnosis of genital herpes by real time PCR in routine clinical practice. Sex Transm Infect 2004; 80 (5) 406-410
• 240 Boivin G. Diagnosis of herpesvirus infections of the central nervous system. Herpes 2004; 11 (Suppl. 02) 48A-56A
• 241 Linssen CF, Jacobs JA, Stelma FF , et al. Herpes simplex virus load in bronchoalveolar lavage fluid is related to poor outcome in critically ill patients. Intensive Care Med 2008; 34 (12) 2202-2209
• 242 Witt MN, Braun GS, Ihrler S, Schmid H. Occurrence of HSV-1-induced pneumonitis in patients under standard immunosuppressive therapy for rheumatic, vasculitic, and connective tissue disease. BMC Pulm Med 2009; 9: 22
• 243 British Society for Antimicrobial Chemotherapy Working Party on Antiviral Therapy. Management of herpes virus infections following transplantation. J Antimicrob Chemother 2000; 45 (6) 729-748
• 244 Chou S, Gallagher JG, Merigan TC. Controlled clinical trial of intravenous acyclovir in heart-transplant patients with mucocutaneous herpes simplex infections. Lancet 1981; 1 (8235) 1392-1394
• 245 Tan HH, Goh CL. Viral infections affecting the skin in organ transplant recipients: epidemiology and current management strategies. Am J Clin Dermatol 2006; 7 (1) 13-29
• 246 Danve-Szatanek C, Aymard M, Thouvenot D , et al. Surveillance network for herpes simplex virus resistance to antiviral drugs: 3-year follow-up. J Clin Microbiol 2004; 42 (1) 242-249
• 247 Wilck MB, Zuckerman RA ; AST Infectious Diseases Community of Practice. Herpes simplex virus in solid organ transplantation. Am J Transplant 2013; 13 (Suppl. 04) 121-127
• 248 Muluneh B, Dean A, Armistead P, Khan T. Successful clearance of cutaneous acyclovir-resistant, foscarnet-refractory herpes virus lesions with topical cidofovir in an allogeneic hematopoietic stem cell transplant patient. J Oncol Pharm Pract 2013; 19 (2) 181-185
• 249 Corey L, Wald A, Patel R , et al; Valacyclovir HSV Transmission Study Group. Once-daily valacyclovir to reduce the risk of transmission of genital herpes. N Engl J Med 2004; 350 (1) 11-20
• 250 Sørensen GV, Rosthøj S, Würtz M, Danielsen TK, Schrøder H. The epidemiology of herpes zoster in 226 children with acute lymphoblastic leukemia. Pediatr Blood Cancer 2011; 57 (6) 993-997
• 251 Su SH, Martel-Laferrière V, Labbé AC , et al. High incidence of herpes zoster in nonmyeloablative hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2011; 17 (7) 1012-1017
• 252 Pergam SA, Forsberg CW, Boeckh MJ , et al. Herpes zoster incidence in a multicenter cohort of solid organ transplant recipients. Transpl Infect Dis 2011; 13 (1) 15-23
• 253 Razonable RR, Brown RA, Humar A, Covington E, Alecock E, Paya CV ; PV16000 Study Group. Herpesvirus infections in solid organ transplant patients at high risk of primary cytomegalovirus disease. J Infect Dis 2005; 192 (8) 1331-1339
• 254 Mustapic Z, Basic-Jukic N, Kes P , et al. Varicella zoster infection in renal transplant recipients: prevalence, complications and outcome. Kidney Blood Press Res 2011; 34 (6) 382-386
• 255 Manuel O, Kumar D, Singer LG, Cobos I, Humar A. Incidence and clinical characteristics of herpes zoster after lung transplantation. J Heart Lung Transplant 2008; 27 (1) 11-16
• 256 Sauerbrei A, Taut J, Zell R, Wutzler P. Resistance testing of clinical varicella-zoster virus strains. Antiviral Res 2011; 90 (3) 242-247
• 257 Gnann Jr JW, Whitley RJ. Clinical practice. Herpes zoster. N Engl J Med 2002; 347 (5) 340-346
• 258 Chow J, Golan Y. Vaccination of solid-organ transplantation candidates. Clin Infect Dis 2009; 49 (10) 1550-1556
• 259 Gershon AA, Gershon MD, Breuer J, Levin MJ, Oaklander AL, Griffiths PD. Advances in the understanding of the pathogenesis and epidemiology of herpes zoster. J Clin Virol 2010; 48 (Suppl. 01) S2-S7
• 260 Wiegering V, Schick J, Beer M , et al. Varicella-zoster virus infections in immunocompromised patients - a single centre 6-years analysis. BMC Pediatr 2011; 11: 31
• 261 Matsuzaki A, Suminoe A, Koga Y , et al. Fatal visceral varicella-zoster virus infection without skin involvement in a child with acute lymphoblastic leukemia. Pediatr Hematol Oncol 2008; 25 (3) 237-242
• 262 Buchbinder SP, Katz MH, Hessol NA , et al. Herpes zoster and human immunodeficiency virus infection. J Infect Dis 1992; 166 (5) 1153-1156
• 263 Gourishankar S, McDermid JC, Jhangri GS, Preiksaitis JK. Herpes zoster infection following solid organ transplantation: incidence, risk factors and outcomes in the current immunosuppressive era. Am J Transplant 2004; 4 (1) 108-115
• 264 Arness T, Pedersen R, Dierkhising R, Kremers W, Patel R. Varicella zoster virus-associated disease in adult kidney transplant recipients: incidence and risk-factor analysis. Transpl Infect Dis 2008; 10 (4) 260-268
• 265 Levitsky J, Kalil A, Meza JL, Hurst GE, Freifeld A. Herpes zoster infection after liver transplantation: a case-control study. Liver Transpl 2005; 11 (3) 320-325
• 266 Herrero JI, Quiroga J, Sangro B , et al. Herpes zoster after liver transplantation: incidence, risk factors, and complications. Liver Transpl 2004; 10 (9) 1140-1143
• 267 Hsu RB, Fang CT, Chang SC , et al. Infectious complications after heart transplantation in Chinese recipients. Am J Transplant 2005; 5 (8) 2011-2016
• 268 Fuks L, Shitrit D, Fox BD , et al. Herpes zoster after lung transplantation: incidence, timing, and outcome. Ann Thorac Surg 2009; 87 (2) 423-426
• 269 Leung TF, Chik KW, Li CK , et al. Incidence, risk factors and outcome of varicella-zoster virus infection in children after haematopoietic stem cell transplantation. Bone Marrow Transplant 2000; 25 (2) 167-172
• 270 Choo PW, Donahue JG, Manson JE, Platt R. The epidemiology of varicella and its complications. J Infect Dis 1995; 172 (3) 706-712
• 271 Weigle KA, Grose C. Varicella pneumonitis: immunodiagnosis with a monoclonal antibody. J Pediatr 1984; 105 (2) 265-269
• 272 Mohsen AH, McKendrick M. Varicella pneumonia in adults. Eur Respir J 2003; 21 (5) 886-891
• 273 Weinstein L, Meade RH. Respiratory manifestations of chicken pox; special consideration of the features of primary varicella pneumonia. AMA Arch Intern Med 1956; 98 (1) 91-99
• 274 Popara M, Pendle S, Sacks L, Smego Jr RA, Mer M. Varicella pneumonia in patients with HIV/AIDS. Int J Infect Dis 2002; 6 (1) 6-8
• 275 Mohsen AH, Peck RJ, Mason Z, Mattock L, McKendrick MW. Lung function tests and risk factors for pneumonia in adults with chickenpox. Thorax 2001; 56 (10) 796-799
• 276 de Jong MD, Weel JF, van Oers MH, Boom R, Wertheim-van Dillen PM. Molecular diagnosis of visceral herpes zoster. Lancet 2001; 357 (9274) 2101-2102
• 277 Dworkin RH, Johnson RW, Breuer J , et al. Recommendations for the management of herpes zoster. Clin Infect Dis 2007; 44 (Suppl. 01) S1-S26
• 278 Brink AA, van Gelder M, Wolffs PF, Bruggeman CA, van Loo IH. Compartmentalization of acyclovir-resistant varicella zoster virus: implications for sampling in molecular diagnostics. Clin Infect Dis 2011; 52 (8) 982-987
• 279 Hatchette T, Tipples GA, Peters G, Alsuwaidi A, Zhou J, Mailman TL. Foscarnet salvage therapy for acyclovir-resistant varicella zoster: report of a novel thymidine kinase mutation and review of the literature. Pediatr Infect Dis J 2008; 27 (1) 75-77
• 280 Lee MY, Kim KS, Lee WK. Intravitreal foscarnet for the treatment of acyclovir-resistant acute retinal necrosis caused by varicella zoster virus. Ocul Immunol Inflamm 2011; 19 (3) 212-213
• 281 Visse B, Dumont B, Huraux JM, Fillet AM. Single amino acid change in DNA polymerase is associated with foscarnet resistance in a varicella-zoster virus strain recovered from a patient with AIDS. J Infect Dis 1998; 178 (Suppl. 01) S55-S57
• 282 Pergam SA, Limaye AP ; AST Infectious Diseases Community of Practice. Varicella zoster virus in solid organ transplantation. Am J Transplant 2013; 13 (Suppl. 04) 138-146
• 283 Rogers JE, Cumpston A, Newton M, Craig M. Onset and complications of varicella zoster reactivation in the autologous hematopoietic cell transplant population. Transpl Infect Dis 2011; 13 (5) 480-484
• 284 Boeckh M, Kim HW, Flowers ME, Meyers JD, Bowden RA. Long-term acyclovir for prevention of varicella zoster virus disease after allogeneic hematopoietic cell transplantation—a randomized double-blind placebo-controlled study. Blood 2006; 107 (5) 1800-1805
• 285 Erard V, Guthrie KA, Varley C , et al. One-year acyclovir prophylaxis for preventing varicella-zoster virus disease after hematopoietic cell transplantation: no evidence of rebound varicella-zoster virus disease after drug discontinuation. Blood 2007; 110 (8) 3071-3077
• 286 Oxman MN, Levin MJ, Johnson GR , et al; Shingles Prevention Study Group. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005; 352 (22) 2271-2284
• 287 Sanford M, Keating GM. Zoster vaccine (Zostavax): a review of its use in preventing herpes zoster and postherpetic neuralgia in older adults. Drugs Aging 2010; 27 (2) 159-176
• 288 Löbermann M, Boršo D, Hilgendorf I, Fritzsche C, Zettl UK, Reisinger EC. Immunization in the adult immunocompromised host. Autoimmun Rev 2012; 11 (3) 212-218
• 289 Avery RK, Michaels M. Update on immunizations in solid organ transplant recipients: what clinicians need to know. Am J Transplant 2008; 8 (1) 9-14
• 290 Cohen JI. Strategies for herpes zoster vaccination of immunocompromised patients. J Infect Dis 2008; 197 (Suppl. 02) S237-S241
• 291 Rubin LG, Levin MJ, Ljungman P , et al; Infectious Diseases Society of America. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis 2014; 58 (3) e44-e100
• 292 Danziger-Isakov L, Kumar D ; AST Infectious Diseases Community of Practice. Vaccination in solid organ transplantation. Am J Transplant 2013; 13 (Suppl. 04) 311-317
• 293 Salahuddin SZ, Ablashi DV, Markham PD , et al. Isolation of a new virus, HBLV, in patients with lymphoproliferative disorders. Science 1986; 234 (4776) 596-601
• 294 Agut H. Deciphering the clinical impact of acute human herpesvirus 6 (HHV-6) infections. J Clin Virol 2011; 52 (3) 164-171
• 295 Ogata M, Fukuda T, Teshima T. Human herpesvirus-6 encephalitis after allogeneic hematopoietic cell transplantation: what we do and do not know. Bone Marrow Transplant 2015; 50 (8) 1030-1036
• 296 De Bolle L, Naesens L, De Clercq E. Update on human herpesvirus 6 biology, clinical features, and therapy. Clin Microbiol Rev 2005; 18 (1) 217-245
• 297 Zerr DM, Meier AS, Selke SS , et al. A population-based study of primary human herpesvirus 6 infection. N Engl J Med 2005; 352 (8) 768-776
• 298 Hall CB, Caserta MT, Schnabel K , et al. Chromosomal integration of human herpesvirus 6 is the major mode of congenital human herpesvirus 6 infection. Pediatrics 2008; 122 (3) 513-520
• 299 Cervera C, Marcos MA, Linares L , et al. A prospective survey of human herpesvirus-6 primary infection in solid organ transplant recipients. Transplantation 2006; 82 (7) 979-982
• 300 Lautenschlager I, Razonable RR. Human herpesvirus-6 infections in kidney, liver, lung, and heart transplantation: review. Transpl Int 2012; 25 (5) 493-502
• 301 Hall CB, Caserta MT, Schnabel KC , et al. Persistence of human herpesvirus 6 according to site and variant: possible greater neurotropism of variant A. Clin Infect Dis 1998; 26 (1) 132-137
• 302 Bates M, Monze M, Bima H , et al. Predominant human herpesvirus 6 variant A infant infections in an HIV-1 endemic region of Sub-Saharan Africa. J Med Virol 2009; 81 (5) 779-789
• 303 Pellett PE, Ablashi DV, Ambros PF , et al. Chromosomally integrated human herpesvirus 6: questions and answers. Rev Med Virol 2012; 22 (3) 144-155
• 304 Leong HN, Tuke PW, Tedder RS , et al. The prevalence of chromosomally integrated human herpesvirus 6 genomes in the blood of UK blood donors. J Med Virol 2007; 79 (1) 45-51
• 305 Yamanishi K, Okuno T, Shiraki K , et al. Identification of human herpesvirus-6 as a causal agent for exanthem subitum. Lancet 1988; 1 (8594) 1065-1067
• 306 Asano Y, Yoshikawa T, Suga S , et al. Viremia and neutralizing antibody response in infants with exanthem subitum. J Pediatr 1989; 114 (4 Pt 1): 535-539
• 307 Asano Y, Yoshikawa T, Suga S , et al. Clinical features of infants with primary human herpesvirus 6 infection (exanthem subitum, roseola infantum). Pediatrics 1994; 93 (1) 104-108
• 308 Zhou W, Lin F, Teng L , et al. Prevalence of herpes and respiratory viruses in induced sputum among hospitalized children with non typical bacterial community-acquired pneumonia. PLoS ONE 2013; 8 (11) e79477
• 309 Hall CB, Long CE, Schnabel KC , et al. Human herpesvirus-6 infection in children. A prospective study of complications and reactivation. N Engl J Med 1994; 331 (7) 432-438
• 310 Pruksananonda P, Hall CB, Insel RA , et al. Primary human herpesvirus 6 infection in young children. N Engl J Med 1992; 326 (22) 1445-1450
• 311 Kositanont U, Wasi C, Wanprapar N , et al. Primary infection of human herpesvirus 6 in children with vertical infection of human immunodeficiency virus type 1. J Infect Dis 1999; 180 (1) 50-55
• 312 Tembo J, Kabwe M, Chilukutu L , et al. Prevalence and risk factors for betaherpesvirus DNAemia in children >3 weeks and <2 years of age admitted to a large referral hospital in sub-Saharan Africa. Clin Infect Dis 2015; 60 (3) 423-431
• 313 Kasolo FC, Mpabalwani E, Gompels UA. Infection with AIDS-related herpesviruses in human immunodeficiency virus-negative infants and endemic childhood Kaposi's sarcoma in Africa. J Gen Virol 1997; 78 (Pt 4): 847-855
• 314 Revest M, Minjolle S, Veyer D, Lagathu G, Michelet C, Colimon R. Detection of HHV-6 in over a thousand samples: new types of infection revealed by an analysis of positive results. J Clin Virol 2011; 51 (1) 20-24
• 315 Al-Zubeidi D, Thangarajh M, Pathak S , et al. Fatal human herpesvirus 6-associated encephalitis in two boys with underlying POLG mitochondrial disorders. Pediatr Neurol 2014; 51 (3) 448-452
• 316 Yao K, Crawford JR, Komaroff AL, Ablashi DV, Jacobson S. Review part 2: Human herpesvirus-6 in central nervous system diseases. J Med Virol 2010; 82 (10) 1669-1678
• 317 Leibovitch EC, Jacobson S. Evidence linking HHV-6 with multiple sclerosis: an update. Curr Opin Virol 2014; 9: 127-133
• 318 Opsahl ML, Kennedy PG. Early and late HHV-6 gene transcripts in multiple sclerosis lesions and normal appearing white matter. Brain 2005; 128 (Pt 3): 516-527
• 319 Yoshikawa T, Ihira M, Suzuki K , et al. Fatal acute myocarditis in an infant with human herpesvirus 6 infection. J Clin Pathol 2001; 54 (10) 792-795
• 320 Comar M, D'Agaro P, Campello C , et al. Human herpes virus 6 in archival cardiac tissues from children with idiopathic dilated cardiomyopathy or congenital heart disease. J Clin Pathol 2009; 62 (1) 80-83
• 321 Caruso A, Favilli F, Rotola A , et al. Human herpesvirus-6 modulates RANTES production in primary human endothelial cell cultures. J Med Virol 2003; 70 (3) 451-458
• 322 Cone RW, Hackman RC, Huang ML , et al. Human herpesvirus 6 in lung tissue from patients with pneumonitis after bone marrow transplantation. N Engl J Med 1993; 329 (3) 156-161
• 323 Buchbinder S, Elmaagacli AH, Schaefer UW, Roggendorf M. Human herpesvirus 6 is an important pathogen in infectious lung disease after allogeneic bone marrow transplantation. Bone Marrow Transplant 2000; 26 (6) 639-644
• 324 Bissinger AL, Einsele H, Hamprecht K , et al. Infectious pulmonary complications after stem cell transplantation or chemotherapy: diagnostic yield of bronchoalveolar lavage. Diagn Microbiol Infect Dis 2005; 52 (4) 275-280
• 325 Inazawa N, Hori T, Hatakeyama N , et al. Large-scale multiplex polymerase chain reaction assay for diagnosis of viral reactivations after allogeneic hematopoietic stem cell transplantation. J Med Virol 2015; 87 (8) 1427-1435
• 326 Razonable RR. Human herpesviruses 6, 7 and 8 in solid organ transplant recipients. Am J Transplant 2013; 13 (Suppl. 03) 67-77 , quiz 77–78
• 327 Humar A, Kumar D, Caliendo AM , et al. Clinical impact of human herpesvirus 6 infection after liver transplantation. Transplantation 2002; 73 (4) 599-604
• 328 Rogers J, Rohal S, Carrigan DR , et al. Human herpesvirus-6 in liver transplant recipients: role in pathogenesis of fungal infections, neurologic complications, and outcome. Transplantation 2000; 69 (12) 2566-2573
• 329 Le J, Gantt S ; AST Infectious Diseases Community of Practice. Human herpesvirus 6, 7 and 8 in solid organ transplantation. Am J Transplant 2013; 13 (Suppl. 04) 128-137
• 330 Endo A, Watanabe K, Ohye T , et al. Molecular and virological evidence of viral activation from chromosomally integrated human herpesvirus 6A in a patient with X-linked severe combined immunodeficiency. Clin Infect Dis 2014; 59 (4) 545-548
• 331 Falasca F, Maida P, Gaeta A , et al. Detection and quantification of EBV, HHV-6 and CMV DNA in the gastrointestinal tract of HIV-positive patients. Infection 2014; 42 (6) 1033-1037
• 332 Safdar A, Brown AE, Malkin M. Acute febrile myelodysplasia and pneumonitis due to human herpesvirus 6 after accelerated chemotherapy. Am J Med 2001; 111 (4) 329-330
• 333 Zerr DM, Boeckh M, Delaney C , et al. HHV-6 reactivation and associated sequelae after hematopoietic cell transplantation. Biol Blood Marrow Transplant 2012; 18 (11) 1700-1708
• 334 Verhoeven DH, Claas EC, Jol-van der Zijde CM , et al. Reactivation of human herpes virus-6 after pediatric stem cell transplantation: risk factors, onset, clinical symptoms and association with severity of acute graft-versus-host disease. Pediatr Infect Dis J 2015; 34 (10) 1118-1127
• 335 Betts BC, Young JA, Ustun C, Cao Q, Weisdorf DJ. Human herpesvirus 6 infection after hematopoietic cell transplantation: is routine surveillance necessary?. Biol Blood Marrow Transplant 2011; 17 (10) 1562-1568
• 336 Van Leer-Buter CC, Sanders JS, Vroom HE, Riezebos-Brilman A, Niesters HG. Human herpesvirus-6 DNAemia is a sign of impending primary CMV infection in CMV sero-discordant renal transplantations. J Clin Virol 2013; 58 (2) 422-426
• 337 Jacobs F, Knoop C, Brancart F , et al; Brussels Heart and Lung Transplantation Group. Human herpesvirus-6 infection after lung and heart-lung transplantation: a prospective longitudinal study. Transplantation 2003; 75 (12) 1996-2001
• 338 Neurohr C, Huppmann P, Leuchte H , et al; Munich Lung Transplant Group. Human herpesvirus 6 in bronchalveolar lavage fluid after lung transplantation: a risk factor for bronchiolitis obliterans syndrome?. Am J Transplant 2005; 5 (12) 2982-2991
• 339 Manuel O, Kumar D, Moussa G , et al. Lack of association between beta-herpesvirus infection and bronchiolitis obliterans syndrome in lung transplant recipients in the era of antiviral prophylaxis. Transplantation 2009; 87 (5) 719-725
• 340 Seo S, Renaud C, Kuypers JM , et al. Idiopathic pneumonia syndrome after hematopoietic cell transplantation: evidence of occult infectious etiologies. Blood 2015; 125 (24) 3789-3797
• 341 Lagadinou ED, Marangos M, Liga M , et al. Human herpesvirus 6-related pure red cell aplasia, secondary graft failure, and clinical severe immune suppression after allogeneic hematopoietic cell transplantation successfully treated with foscarnet. Transpl Infect Dis 2010; 12 (5) 437-440
• 342 Zerr DM, Corey L, Kim HW, Huang ML, Nguy L, Boeckh M. Clinical outcomes of human herpesvirus 6 reactivation after hematopoietic stem cell transplantation. Clin Infect Dis 2005; 40 (7) 932-940
• 343 Dulery R, Salleron J, Dewilde A , et al. Early human herpesvirus type 6 reactivation after allogeneic stem cell transplantation: a large-scale clinical study. Biol Blood Marrow Transplant 2012; 18 (7) 1080-1089
• 344 Amo K, Tanaka-Taya K, Inagi R , et al. Human herpesvirus 6B infection of the large intestine of patients with diarrhea. Clin Infect Dis 2003; 36 (1) 120-123
• 345 Halme L, Arola J, Höckerstedt K, Lautenschlager I. Human herpesvirus 6 infection of the gastroduodenal mucosa. Clin Infect Dis 2008; 46 (3) 434-439
• 346 Lamoth F, Jayet PY, Aubert JD , et al. Case report: human herpesvirus 6 reactivation associated with colitis in a lung transplant recipient. J Med Virol 2008; 80 (10) 1804-1807
• 347 Ogata M, Satou T, Kawano R , et al. Plasma HHV-6 viral load-guided preemptive therapy against HHV-6 encephalopathy after allogeneic stem cell transplantation: a prospective evaluation. Bone Marrow Transplant 2008; 41 (3) 279-285
• 348 Ogata M, Satou T, Kawano R , et al. Correlations of HHV-6 viral load and plasma IL-6 concentration with HHV-6 encephalitis in allogeneic stem cell transplant recipients. Bone Marrow Transplant 2010; 45 (1) 129-136
• 349 Hill JA, Koo S, Guzman Suarez BB , et al. Cord-blood hematopoietic stem cell transplant confers an increased risk for human herpesvirus-6-associated acute limbic encephalitis: a cohort analysis. Biol Blood Marrow Transplant 2012; 18 (11) 1638-1648
• 350 Bhanushali MJ, Kranick SM, Freeman AF , et al. Human herpes 6 virus encephalitis complicating allogeneic hematopoietic stem cell transplantation. Neurology 2013; 80 (16) 1494-1500
• 351 Pischke S, Gösling J, Engelmann I , et al. High intrahepatic HHV-6 virus loads but neither CMV nor EBV are associated with decreased graft survival after diagnosis of graft hepatitis. J Hepatol 2012; 56 (5) 1063-1069
• 352 Härmä M, Höckerstedt K, Lautenschlager I. The long-term outcomes of patients transplanted due to acute liver failure with hepatic human herpesvirus-6 infection. Transplant Proc 2013; 45 (5) 1910-1912
• 353 Pilmore H, Collins J, Dittmer I , et al. Fatal human herpesvirus-6 infection after renal transplantation. Transplantation 2009; 88 (6) 762-765
• 354 Moschettini D, De Milito A, Catucci M , et al. Detection of human herpesviruses 6 and 7 in heart transplant recipients by a multiplex polymerase chain reaction method. Eur J Clin Microbiol Infect Dis 1998; 17 (2) 117-119
• 355 Yoshida M, Nakamae H, Okamura H , et al. Pericarditis associated with human herpesvirus-6 reactivation in a patient after unrelated cord blood transplant. Exp Clin Transplant 2015;
• 356 Nash PJ, Avery RK, Tang WH, Starling RC, Taege AJ, Yamani MH. Encephalitis owing to human herpesvirus-6 after cardiac transplant. Am J Transplant 2004; 4 (7) 1200-1203
• 357 Michaelides A, Glare EM, Spelman DW , et al. beta-Herpesvirus (human cytomegalovirus and human herpesvirus 6) reactivation in at-risk lung transplant recipients and in human immunodeficiency virus-infected patients. J Infect Dis 2002; 186 (2) 173-180
• 358 Costa C, Curtoni A, Bergallo M , et al. Quantitative detection of HHV-6 and HHV-7 in transbronchial biopsies from lung transplant recipients. New Microbiol 2011; 34 (3) 275-280
• 359 Lehto JT, Halme M, Tukiainen P, Harjula A, Sipponen J, Lautenschlager I. Human herpesvirus-6 and -7 after lung and heart-lung transplantation. J Heart Lung Transplant 2007; 26 (1) 41-47
• 360 Fairfax MR, Schacker T, Cone RW, Collier AC, Corey L. Human herpesvirus 6 DNA in blood cells of human immunodeficiency virus-infected men: correlation of high levels with high CD4 cell counts. J Infect Dis 1994; 169 (6) 1342-1345
• 361 Fabio G, Knight SN, Kidd IM , et al. Prospective study of human herpesvirus 6, human herpesvirus 7, and cytomegalovirus infections in human immunodeficiency virus-positive patients. J Clin Microbiol 1997; 35 (10) 2657-2659
• 362 Pinheiro RdosS, Ferreira DdeC, Nóbrega F, Santos NS, Souza IP, Castro GF. Current status of herpesvirus identification in the oral cavity of HIV-infected children. Rev Soc Bras Med Trop 2013; 46 (1) 15-19
• 363 De Clercq E, Naesens L, De Bolle L, Schols D, Zhang Y, Neyts J. Antiviral agents active against human herpesviruses HHV-6, HHV-7 and HHV-8. Rev Med Virol 2001; 11 (6) 381-395
• 364 Ljungman P. Beta-herpesvirus challenges in the transplant recipient. J Infect Dis 2002; 186 (Suppl. 01) S99-S109
• 365 Ishiyama K, Katagiri T, Hoshino T, Yoshida T, Yamaguchi M, Nakao S. Preemptive therapy of human herpesvirus-6 encephalitis with foscarnet sodium for high-risk patients after hematopoietic SCT. Bone Marrow Transplant 2011; 46 (6) 863-869
• 366 Gerdemann U, Keukens L, Keirnan JM , et al. Immunotherapeutic strategies to prevent and treat human herpesvirus 6 reactivation after allogeneic stem cell transplantation. Blood 2013; 121 (1) 207-218
• 367 Frenkel N, Schirmer EC, Wyatt LS , et al. Isolation of a new herpesvirus from human CD4+ T cells. Proc Natl Acad Sci U S A 1990; 87 (2) 748-752
• 368 Berneman ZN, Ablashi DV, Li G , et al. Human herpesvirus 7 is a T-lymphotropic virus and is related to, but significantly different from, human herpesvirus 6 and human cytomegalovirus. Proc Natl Acad Sci U S A 1992; 89 (21) 10552-10556
• 369 Ward KN. The natural history and laboratory diagnosis of human herpesviruses-6 and -7 infections in the immunocompetent. J Clin Virol 2005; 32 (3) 183-193
• 370 Dockrell DH, Paya CV. Human herpesvirus-6 and -7 in transplantation. Rev Med Virol 2001; 11 (1) 23-36
• 371 Clark DA, Freeland ML, Mackie LK, Jarrett RF, Onions DE. Prevalence of antibody to human herpesvirus 7 by age. J Infect Dis 1993; 168 (1) 251-252
• 372 Ward KN, Andrews NJ, Verity CM, Miller E, Ross EM. Human herpesviruses-6 and -7 each cause significant neurological morbidity in Britain and Ireland. Arch Dis Child 2005; 90 (6) 619-623
• 373 Caserta MT, Hall CB, Schnabel K, Long CE, D'Heron N. Primary human herpesvirus 7 infection: a comparison of human herpesvirus 7 and human herpesvirus 6 infections in children. J Pediatr 1998; 133 (3) 386-389
• 374 Kimberlin DW. Human herpesviruses 6 and 7: identification of newly recognized viral pathogens and their association with human disease. Pediatr Infect Dis J 1998; 17 (1) 59-67 , quiz 68
• 375 Tanaka K, Kondo T, Torigoe S, Okada S, Mukai T, Yamanishi K. Human herpesvirus 7: another causal agent for roseola (exanthem subitum). J Pediatr 1994; 125 (1) 1-5
• 376 Epstein LG, Shinnar S, Hesdorffer DC , et al; FEBSTAT study team. Human herpesvirus 6 and 7 in febrile status epilepticus: the FEBSTAT study. Epilepsia 2012; 53 (9) 1481-1488
• 377 Schwartz KL, Richardson SE, Ward KN , et al. Delayed primary HHV-7 infection and neurologic disease. Pediatrics 2014; 133 (6) e1541-e1547
• 378 Humar A, Asberg A, Kumar D , et al; VICTOR study group. An assessment of herpesvirus co-infections in patients with CMV disease: correlation with clinical and virologic outcomes. Am J Transplant 2009; 9 (2) 374-381
• 379 Safronetz D, Humar A, Tipples GA. Differentiation and quantitation of human herpesviruses 6A, 6B and 7 by real-time PCR. J Virol Methods 2003; 112 (1–2) 99-105
• 380 Chang Y, Cesarman E, Pessin MS , et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 1994; 266 (5192) 1865-1869
• 381 Schulz TF, Cesarman E. Kaposi Sarcoma-associated Herpesvirus: mechanisms of oncogenesis. Curr Opin Virol 2015; 14: 116-128
• 382 Dow DE, Cunningham CK, Buchanan AM. A review of human herpesvirus 8, the Kaposi's sarcoma-associated herpesvirus, in the pediatric population. J Pediatric Infect Dis Soc 2014; 3 (1) 66-76
• 383 Hleyhel M, Belot A, Bouvier AM , et al; FHDH-ANRS CO4. Trends in survival after cancer diagnosis among HIV-infected individuals between 1992 and 2009. Results from the FHDH-ANRS CO4 cohort. Int J Cancer 2015; 137 (10) 2443-2453
• 384 Dittmer DP, Damania B. Kaposi sarcoma associated herpesvirus pathogenesis (KSHV)—an update. Curr Opin Virol 2013; 3 (3) 238-244
• 385 Cesarman E, Chang Y, Moore PS, Said JW, Knowles DM. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. N Engl J Med 1995; 332 (18) 1186-1191
• 386 Régnier-Rosencher E, Barrou B, Marcelin AG , et al. [Primary effusion lymphoma in two kidney transplant recipients]. Ann Dermatol Venereol 2010; 137 (4) 285-289
• 387 Liao G, Cai J, Yue C, Qing X. Extracavitary/solid variant of primary effusion lymphoma presenting as a gastric mass. Exp Mol Pathol 2015; 99 (3) 445-448
• 388 Sullivan RJ, Pantanowitz L, Casper C, Stebbing J, Dezube BJ. HIV/AIDS: epidemiology, pathophysiology, and treatment of Kaposi sarcoma-associated herpesvirus disease: Kaposi sarcoma, primary effusion lymphoma, and multicentric Castleman disease. Clin Infect Dis 2008; 47 (9) 1209-1215
• 389 Vijgen S, Wyss C, Meylan P , et al. Fatal outcome of multiple clinical presentations of human herpesvirus 8-related disease after solid organ transplantation. Transplantation 2016; 100 (1) 134-140
• 390 Li CF, Ye H, Liu H, Du MQ, Chuang SS. Fatal HHV-8-associated hemophagocytic syndrome in an HIV-negative immunocompetent patient with plasmablastic variant of multicentric Castleman disease (plasmablastic microlymphoma). Am J Surg Pathol 2006; 30 (1) 123-127
• 391 Grossman WJ, Radhi M, Schauer D, Gerday E, Grose C, Goldman FD. Development of hemophagocytic lymphohistiocytosis in triplets infected with HHV-8. Blood 2005; 106 (4) 1203-1206
• 392 Stebbing J, Ngan S, Ibrahim H , et al. The successful treatment of haemophagocytic syndrome in patients with human immunodeficiency virus-associated multi-centric Castleman's disease. Clin Exp Immunol 2008; 154 (3) 399-405
• 393 Tornesello ML, Biryahwaho B, Downing R , et al. Human herpesvirus type 8 variants circulating in Europe, Africa and North America in classic, endemic and epidemic Kaposi's sarcoma lesions during pre-AIDS and AIDS era. Virology 2010; 398 (2) 280-289
• 394 Wakeham K, Johnston WT, Nalwoga A , et al. Trends in Kaposi's sarcoma-associated Herpesvirus antibodies prior to the development of HIV-associated Kaposi's sarcoma: a nested case-control study. Int J Cancer 2015; 136 (12) 2822-2830
• 395 De Bruin GP, Stefan DC. Children with Kaposi sarcoma in two southern African hospitals: clinical presentation, management, and outcome. J Trop Med 2013; 2013: 213490
• 396 Stein L, Urban MI, O'Connell D , et al. The spectrum of human immunodeficiency virus-associated cancers in a South African black population: results from a case-control study, 1995-2004. Int J Cancer 2008; 122 (10) 2260-2265
• 397 Ngalamika O, Minhas V, Wood C. Kaposi's sarcoma at the University Teaching Hospital, Lusaka, Zambia in the antiretroviral therapy era. Int J Cancer 2015; 136 (5) 1241-1242
• 398 Ziegler J, Newton R, Bourboulia D , et al; Uganda Kaposi's Sarcoma Study Group. Risk factors for Kaposi's sarcoma: a case-control study of HIV-seronegative people in Uganda. Int J Cancer 2003; 103 (2) 233-240
• 399 Shebl FM, Dollard SC, Pfeiffer RM , et al. Human herpesvirus 8 seropositivity among sexually active adults in Uganda. PLoS ONE 2011; 6 (6) e21286
• 400 Minhas V, Brayfield BP, Crabtree KL, Kankasa C, Mitchell CD, Wood C. Primary gamma-herpesviral infection in Zambian children. BMC Infect Dis 2010; 10: 115
• 401 Kim Y, Leventaki V, Bhaijee F, Jackson CC, Medeiros LJ, Vega F. Extracavitary/solid variant of primary effusion lymphoma. Ann Diagn Pathol 2012; 16 (6) 441-446
• 402 Butler LM, Were WA, Balinandi S , et al. Human herpesvirus 8 infection in children and adults in a population-based study in rural Uganda. J Infect Dis 2011; 203 (5) 625-634
• 403 Wakeham K, Webb EL, Sebina I , et al. Risk factors for seropositivity to Kaposi sarcoma-associated herpesvirus among children in Uganda. J Acquir Immune Defic Syndr 2013; 63 (2) 228-233
• 404 La Ferla L, Pinzone MR, Nunnari G , et al. Kaposi' s sarcoma in HIV-positive patients: the state of art in the HAART-era. Eur Rev Med Pharmacol Sci 2013; 17 (17) 2354-2365
• 405 Mohanna S, Maco V, Bravo F, Gotuzzo E. Epidemiology and clinical characteristics of classic Kaposi's sarcoma, seroprevalence, and variants of human herpesvirus 8 in South America: a critical review of an old disease. Int J Infect Dis 2005; 9 (5) 239-250
• 406 de Sanjose S, Mbisa G, Perez-Alvarez S , et al. Geographic variation in the prevalence of Kaposi sarcoma-associated herpesvirus and risk factors for transmission. J Infect Dis 2009; 199 (10) 1449-1456
• 407 Dukers NH, Rezza G. Human herpesvirus 8 epidemiology: what we do and do not know. AIDS 2003; 17 (12) 1717-1730
• 408 Dedicoat M, Newton R, Alkharsah KR , et al. Mother-to-child transmission of human herpesvirus-8 in South Africa. J Infect Dis 2004; 190 (6) 1068-1075
• 409 Casper C, Redman M, Huang ML , et al. HIV infection and human herpesvirus-8 oral shedding among men who have sex with men. J Acquir Immune Defic Syndr 2004; 35 (3) 233-238
• 410 Taylor MM, Chohan B, Lavreys L , et al. Shedding of human herpesvirus 8 in oral and genital secretions from HIV-1-seropositive and -seronegative Kenyan women. J Infect Dis 2004; 190 (3) 484-488
• 411 Engels EA, Atkinson JO, Graubard BI , et al. Risk factors for human herpesvirus 8 infection among adults in the United States and evidence for sexual transmission. J Infect Dis 2007; 196 (2) 199-207
• 412 Hladik W, Dollard SC, Mermin J , et al. Transmission of human herpesvirus 8 by blood transfusion. N Engl J Med 2006; 355 (13) 1331-1338
• 413 Luppi M, Barozzi P, Santagostino G , et al. Molecular evidence of organ-related transmission of Kaposi sarcoma-associated herpesvirus or human herpesvirus-8 in transplant patients. Blood 2000; 96 (9) 3279-3281
• 414 Barozzi P, Luppi M, Facchetti F , et al. Post-transplant Kaposi sarcoma originates from the seeding of donor-derived progenitors. Nat Med 2003; 9 (5) 554-561
• 415 Wang QJ, Jenkins FJ, Jacobson LP , et al. Primary human herpesvirus 8 infection generates a broadly specific CD8(+) T-cell response to viral lytic cycle proteins. Blood 2001; 97 (8) 2366-2373
• 416 Bhutani M, Polizzotto MN, Uldrick TS, Yarchoan R. Kaposi sarcoma-associated herpesvirus-associated malignancies: epidemiology, pathogenesis, and advances in treatment. Semin Oncol 2015; 42 (2) 223-246
• 417 Rohner E, Wyss N, Heg Z , et al. HIV and human herpesvirus 8 co-infection across the globe: Systematic review and meta-analysis. Int J Cancer 2016; 138 (1) 45-54
• 418 Celtik C, Unüvar A, Aydoğan A , et al. Human herpes virus type 8-associated Kaposi sarcoma in a pediatric liver transplant recipient. Pediatr Transplant 2011; 15 (5) E100-E104
• 419 Ariza-Heredia EJ, Razonable RR. Human herpes virus 8 in solid organ transplantation. Transplantation 2011; 92 (8) 837-844
• 420 Jackson CC, Dickson MA, Sadjadi M , et al. Kaposi sarcoma of childhood: inborn or acquired immunodeficiency to oncogenic HHV-8. Pediatr Blood Cancer 2016; 63 (3) 392-397
• 421 Tedeschi R, Marus A, Bidoli E, Simonelli C, De Paoli P. Human herpesvirus 8 DNA quantification in matched plasma and PBMCs samples of patients with HHV8-related lymphoproliferative diseases. J Clin Virol 2008; 43 (3) 255-259
• 422 Tedeschi R, Enbom M, Bidoli E, Linde A, De Paoli P, Dillner J. Viral load of human herpesvirus 8 in peripheral blood of human immunodeficiency virus-infected patients with Kaposi's sarcoma. J Clin Microbiol 2001; 39 (12) 4269-4273
• 423 Pantanowitz L, Otis CN, Dezube BJ. Immunohistochemistry in Kaposi's sarcoma. Clin Exp Dermatol 2010; 35 (1) 68-72
• 424 Chu KM, Mahlangeni G, Swannet S, Ford NP, Boulle A, Van Cutsem G. AIDS-associated Kaposi's sarcoma is linked to advanced disease and high mortality in a primary care HIV programme in South Africa. J Int AIDS Soc 2010; 13: 23
• 425 Régnier-Rosencher E, Guillot B, Dupin N. Treatments for classic Kaposi sarcoma: a systematic review of the literature. J Am Acad Dermatol 2013; 68 (2) 313-331
• 426 Mohanlal RD, Pather S. Kaposi's sarcoma, a South African perspective: Demographic and pathological features. S Afr Med J 2015; 105 (5) 375-378
• 427 Sissolak G, Mayaud P. AIDS-related Kaposi's sarcoma: epidemiological, diagnostic, treatment and control aspects in sub-Saharan Africa. Trop Med Int Health 2005; 10 (10) 981-992
• 428 Feller L, Khammissa RA, Gugushe TS , et al. HIV-associated Kaposi sarcoma in African children. SADJ 2010; 65 (1) 20-22
• 429 Mwakigonja AR, Pak F, Pyakurel P , et al. Oral Kaposi's sarcoma in Tanzania: presentation, immunopathology and human herpesvirus-8 association. Oncol Rep 2007; 17 (6) 1291-1299
• 430 O'Brien TR, Kedes D, Ganem D , et al. Evidence for concurrent epidemics of human herpesvirus 8 and human immunodeficiency virus type 1 in US homosexual men: rates, risk factors, and relationship to Kaposi's sarcoma. J Infect Dis 1999; 180 (4) 1010-1017
• 431 International Collaboration on HIV and Cancer. Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults. J Natl Cancer Inst 2000; 92 (22) 1823-1830
• 432 Shiels MS, Pfeiffer RM, Gail MH , et al. Cancer burden in the HIV-infected population in the United States. J Natl Cancer Inst 2011; 103 (9) 753-762
• 433 Khalil AM, Carette MF, Cadranel JL, Mayaud CM, Bigot JM. Intrathoracic Kaposi's sarcoma. CT findings. Chest 1995; 108 (6) 1622-1626
• 434 Hamm PG, Judson MA, Aranda CP. Diagnosis of pulmonary Kaposi's sarcoma with fiberoptic bronchoscopy and endobronchial biopsy. A report of five cases. Cancer 1987; 59 (4) 807-810
• 435 Leidner RS, Aboulafia DM. Recrudescent Kaposi's sarcoma after initiation of HAART: a manifestation of immune reconstitution syndrome. AIDS Patient Care STDS 2005; 19 (10) 635-644
• 436 Caponetti G, Dezube BJ, Restrepo CS, Pantanowitz L. Kaposi sarcoma of the musculoskeletal system: a review of 66 patients. Cancer 2007; 109 (6) 1040-1052
• 437 Guihot A, Dupin N, Marcelin AG , et al. Low T cell responses to human herpesvirus 8 in patients with AIDS-related and classic Kaposi sarcoma. J Infect Dis 2006; 194 (8) 1078-1088
• 438 Stallone G, Schena A, Infante B , et al. Sirolimus for Kaposi's sarcoma in renal-transplant recipients. N Engl J Med 2005; 352 (13) 1317-1323
• 439 Hosseini-Moghaddam SM, Soleimanirahbar A, Mazzulli T, Rotstein C, Husain S. Post renal transplantation Kaposi's sarcoma: a review of its epidemiology, pathogenesis, diagnosis, clinical aspects, and therapy. Transpl Infect Dis 2012; 14 (4) 338-345
• 440 Casper C. The aetiology and management of Castleman disease at 50 years: translating pathophysiology to patient care. Br J Haematol 2005; 129 (1) 3-17
• 441 Uldrick TS, Polizzotto MN, Aleman K , et al. High-dose zidovudine plus valganciclovir for Kaposi sarcoma herpesvirus-associated multicentric Castleman disease: a pilot study of virus-activated cytotoxic therapy. Blood 2011; 117 (26) 6977-6986
• 442 Lumley S, Madge S, Nugent D , et al. High-level human herpesvirus-8 viremia and multicentric Castleman's disease following initiation of highly active antiretroviral therapy. AIDS 2014; 28 (11) 1698-1700
• 443 Andrei G, Snoeck R. Kaposi's sarcoma-associated herpesvirus: the role of lytic replication in targeted therapy. Curr Opin Infect Dis 2015; 28 (6) 611-624
• 444 Carbone A, De Paoli P, Gloghini A, Vaccher E. KSHV-associated multicentric Castleman disease: A tangle of different entities requiring multitarget treatment strategies. Int J Cancer 2015; 137 (2) 251-261
• 445 Stebbing J, Pantanowitz L, Dayyani F, Sullivan RJ, Bower M, Dezube BJ. HIV-associated multicentric Castleman's disease. Am J Hematol 2008; 83 (6) 498-503
• 446 Gérard L, Bérezné A, Galicier L , et al. Prospective study of rituximab in chemotherapy-dependent human immunodeficiency virus associated multicentric Castleman's disease: ANRS 117 CastlemaB Trial. J Clin Oncol 2007; 25 (22) 3350-3356
• 447 Mylona EE, Baraboutis IG, Lekakis LJ, Georgiou O, Papastamopoulos V, Skoutelis A. Multicentric Castleman's disease in HIV infection: a systematic review of the literature. AIDS Rev 2008; 10 (1) 25-35
• 448 Al Otaibi T, Al Sagheir A, Ludwin D, Meyer R. Post renal transplant Castleman's disease resolved after graft nephrectomy: a case report. Transplant Proc 2007; 39 (4) 1276-1277
• 449 Gaitonde S, Vidanovic V, Ni H. Concomitant and fatal HHV-8+ multicentric Castleman's disease and Kaposi's sarcoma in the same lymph node of an HIV- liver transplant patient. Histopathology 2007; 50 (7) 954-958
• 450 Lim EJ, Crowley P, Mitchell CA, Angus PW. Post-liver transplantation multicentric Castleman disease treated with valganciclovir and weaning of immunosuppression. Am J Transplant 2011; 11 (1) 169-172
• 451 Rokx C, Rijnders BJ, van Laar JA. Treatment of multicentric Castleman's disease in HIV-1 infected and uninfected patients: a systematic review. Neth J Med 2015; 73 (5) 202-210
• 452 Oksenhendler E, Boulanger E, Galicier L , et al. High incidence of Kaposi sarcoma-associated herpesvirus-related non-Hodgkin lymphoma in patients with HIV infection and multicentric Castleman disease. Blood 2002; 99 (7) 2331-2336
• 453 Uldrick TS, Wang V, O'Mahony D , et al. An interleukin-6-related systemic inflammatory syndrome in patients co-infected with Kaposi sarcoma-associated herpesvirus and HIV but without Multicentric Castleman disease. Clin Infect Dis 2010; 51 (3) 350-358
• 454 Knowles DM, Inghirami G, Ubriaco A, Dalla-Favera R. Molecular genetic analysis of three AIDS-associated neoplasms of uncertain lineage demonstrates their B-cell derivation and the possible pathogenetic role of the Epstein-Barr virus. Blood 1989; 73 (3) 792-799
• 455 Nador RG, Cesarman E, Chadburn A , et al. Primary effusion lymphoma: a distinct clinicopathologic entity associated with the Kaposi's sarcoma-associated herpes virus. Blood 1996; 88 (2) 645-656
• 456 Chadburn A, Hyjek E, Mathew S, Cesarman E, Said J, Knowles DM. KSHV-positive solid lymphomas represent an extra-cavitary variant of primary effusion lymphoma. Am J Surg Pathol 2004; 28 (11) 1401-1416
• 457 Jenner RG, Maillard K, Cattini N , et al. Kaposi's sarcoma-associated herpesvirus-infected primary effusion lymphoma has a plasma cell gene expression profile. Proc Natl Acad Sci U S A 2003; 100 (18) 10399-10404
• 458 Brimo F, Michel RP, Khetani K, Auger M. Primary effusion lymphoma: a series of 4 cases and review of the literature with emphasis on cytomorphologic and immunocytochemical differential diagnosis. Cancer 2007; 111 (4) 224-233
• 459 Simonelli C, Spina M, Cinelli R , et al. Clinical features and outcome of primary effusion lymphoma in HIV-infected patients: a single-institution study. J Clin Oncol 2003; 21 (21) 3948-3954
• 460 Boulanger E, Afonso PV, Yahiaoui Y, Adle-Biassette H, Gabarre J, Agbalika F. Human herpesvirus-8 (HHV-8)-associated primary effusion lymphoma in two renal transplant recipients receiving rapamycin. Am J Transplant 2008; 8 (3) 707-710
• 461 Dotti G, Fiocchi R, Motta T , et al. Primary effusion lymphoma after heart transplantation: a new entity associated with human herpesvirus-8. Leukemia 1999; 13 (5) 664-670
• 462 Jones D, Ballestas ME, Kaye KM , et al. Primary-effusion lymphoma and Kaposi's sarcoma in a cardiac-transplant recipient. N Engl J Med 1998; 339 (7) 444-449
• 463 Meng YX, Spira TJ, Bhat GJ , et al. Individuals from North America, Australasia, and Africa are infected with four different genotypes of human herpesvirus 8. Virology 1999; 261 (1) 106-119
• 464 Schulz TF. Epidemiology of Kaposi's sarcoma-associated herpesvirus/human herpesvirus 8. Adv Cancer Res 1999; 76: 121-160
• 465 Carbone A, Gaidano G. HHV-8-positive body-cavity-based lymphoma: a novel lymphoma entity. Br J Haematol 1997; 97 (3) 515-522
• 466 Pielasinski U, Santonja C, Rodríguez-Pinilla SM, Requena L. Extracavitary primary effusion lymphoma presenting as a cutaneous tumor: a case report and literature review. J Cutan Pathol 2014; 41 (9) 745-753
• 467 Wamburu G, Masenga EJ, Moshi EZ, Schmid-Grendelmeier P, Kempf W, Orfanos CE. HIV - associated and non - HIV associated types of Kaposi's sarcoma in an African population in Tanzania. Status of immune suppression and HHV-8 seroprevalence. Eur J Dermatol 2006; 16 (6) 677-682
• 468 Palmieri C, Dhillon T, Thirlwell C , et al. Pulmonary Kaposi sarcoma in the era of highly active antiretroviral therapy. HIV Med 2006; 7 (5) 291-293
• 469 Danzig JB, Brandt LJ, Reinus JF, Klein RS. Gastrointestinal malignancy in patients with AIDS. Am J Gastroenterol 1991; 86 (6) 715-718
• 470 Nasti G, Talamini R, Antinori A , et al; AIDS Clinical Trial Group Staging System in the Haart Era--the Italian Cooperative Group on AIDS and Tumors and the Italian Cohort of Patients Naive from Antiretrovirals. AIDS-related Kaposi's Sarcoma: evaluation of potential new prognostic factors and assessment of the AIDS Clinical Trial Group Staging System in the Haart Era—the Italian Cooperative Group on AIDS and Tumors and the Italian Cohort of Patients Naive From Antiretrovirals. J Clin Oncol 2003; 21 (15) 2876-2882
• 471 Semeere AS, Busakhala N, Martin JN. Impact of antiretroviral therapy on the incidence of Kaposi's sarcoma in resource-rich and resource-limited settings. Curr Opin Oncol 2012; 24 (5) 522-530
• 472 Chagaluka G, Stanley C, Banda K , et al. Kaposi's sarcoma in children: an open randomised trial of vincristine, oral etoposide and a combination of vincristine and bleomycin. Eur J Cancer 2014; 50 (8) 1472-1481
• 473 Gantt S, Casper C. Human herpesvirus 8-associated neoplasms: the roles of viral replication and antiviral treatment. Curr Opin Infect Dis 2011; 24 (4) 295-301
• 474 Aaron L, Lidove O, Yousry C, Roudiere L, Dupont B, Viard JP. Human herpesvirus 8-positive Castleman disease in human immunodeficiency virus-infected patients: the impact of highly active antiretroviral therapy. Clin Infect Dis 2002; 35 (7) 880-882
• 475 van Rhee F, Wong RS, Munshi N , et al. Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial. Lancet Oncol 2014; 15 (9) 966-974
• 476 Gérard L, Michot JM, Burcheri S , et al. Rituximab decreases the risk of lymphoma in patients with HIV-associated multicentric Castleman disease. Blood 2012; 119 (10) 2228-2233
• 477 Bower M, Powles T, Williams S , et al. Brief communication: rituximab in HIV-associated multicentric Castleman disease. Ann Intern Med 2007; 147 (12) 836-839
• 478 Bower M, Newsom-Davis T, Naresh K , et al. Clinical features and outcome in HIV-associated multicentric Castleman's disease. J Clin Oncol 2011; 29 (18) 2481-2486
• 479 Halfdanarson TR, Markovic SN, Kalokhe U, Luppi M. A non-chemotherapy treatment of a primary effusion lymphoma: durable remission after intracavitary cidofovir in HIV negative PEL refractory to chemotherapy. Ann Oncol 2006; 17 (12) 1849-1850
• 480 Luppi M, Trovato R, Barozzi P , et al. Treatment of herpesvirus associated primary effusion lymphoma with intracavity cidofovir. Leukemia 2005; 19 (3) 473-476
• 481 Sin SH, Roy D, Wang L , et al. Rapamycin is efficacious against primary effusion lymphoma (PEL) cell lines in vivo by inhibiting autocrine signaling. Blood 2007; 109 (5) 2165-2173
• 482 An J, Sun Y, Fisher M, Rettig MB. Antitumor effects of bortezomib (PS-341) on primary effusion lymphomas. Leukemia 2004; 18 (10) 1699-1704